<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antidepressants for treating depression in dementia - Dudas, R - 2018 | Cochrane Library</title> <meta content="Antidepressants for treating depression in dementia - Dudas, R - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003944.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antidepressants for treating depression in dementia - Dudas, R - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003944.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003944.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antidepressants for treating depression in dementia" name="citation_title"/> <meta content="Robert Dudas" name="citation_author"/> <meta content="rbd21@cam.ac.uk" name="citation_author_email"/> <meta content="Reem Malouf" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Jenny McCleery" name="citation_author"/> <meta content="Oxford Health NHS Foundation Trust" name="citation_author_institution"/> <meta content="Tom Dening" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD003944.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/08/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003944.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003944.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003944.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Activities of Daily Living; Antidepressive Agents [*therapeutic use]; Cognition; Dementia [*psychology]; Depression [*drug therapy]; Patient Dropouts [statistics &amp; numerical data]; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003944.pub2&amp;doi=10.1002/14651858.CD003944.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003944\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003944\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","ms","pl","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003944.pub2",title:"Antidepressants for treating depression in dementia",firstPublishedDate:"Aug 31, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003944.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003944.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003944.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003944.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003944.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003944.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003944.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003944.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003944.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003944.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13678 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003944.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-sec-0079"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-sec-0073"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/appendices#CD003944-sec-0084"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/table_n/CD003944StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/table_n/CD003944StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antidepressants for treating depression in dementia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/information#CD003944-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Robert Dudas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/information#CD003944-cr-0003">Reem Malouf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/information#CD003944-cr-0004">Jenny McCleery</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003944.pub2/information#CD003944-cr-0005">Tom Dening</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/information/en#CD003944-sec-0090">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 August 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003944.pub2">https://doi.org/10.1002/14651858.CD003944.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003944-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003944-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003944-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003944-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003944-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003944-abs-0001" lang="en"> <section id="CD003944-sec-0001"> <h3 class="title" id="CD003944-sec-0001">Background</h3> <p>The use of antidepressants in dementia accompanied by depressive symptoms is widespread, but their clinical efficacy is uncertain. This review updates an earlier version, first published in 2002. </p> </section> <section id="CD003944-sec-0002"> <h3 class="title" id="CD003944-sec-0002">Objectives</h3> <p>To determine the efficacy and safety of any type of antidepressant for patients who have been diagnosed as having dementia of any type and depression as defined by recognised criteria. </p> </section> <section id="CD003944-sec-0003"> <h3 class="title" id="CD003944-sec-0003">Search methods</h3> <p>We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group’s Specialised Register, on 16 August 2017. ALOIS contains information on trials retrieved from databases and from a number of trial registers and grey literature sources. </p> </section> <section id="CD003944-sec-0004"> <h3 class="title" id="CD003944-sec-0004">Selection criteria</h3> <p>We included all relevant double‐blind, randomised trials comparing any antidepressant drug with placebo, for patients diagnosed as having dementia and depression. </p> </section> <section id="CD003944-sec-0005"> <h3 class="title" id="CD003944-sec-0005">Data collection and analysis</h3> <p>Two review authors selected studies for inclusion and extracted data independently. We assessed risk of bias in the included studies using the Cochrane 'Risk of bias' tool. Where clinically appropriate, we pooled data for treatment periods up to three months and from three to nine months. We used GRADE methods to assess the overall quality of the evidence. </p> </section> <section id="CD003944-sec-0006"> <h3 class="title" id="CD003944-sec-0006">Main results</h3> <p>We included ten studies with a total of 1592 patients. Eight included studies reported sufficiently detailed results to enter into analyses related to antidepressant efficacy. We split one study which included two different antidepressants and therefore had nine groups of patients treated with antidepressants compared with nine groups receiving placebo treatment. Information needed to make 'Risk of bias' judgements was often missing. </p> <p>We found high‐quality evidence of little or no difference in scores on depression symptom rating scales between the antidepressant and placebo treated groups after 6 to 13 weeks (standardised mean difference (SMD) ‐0.10, 95% confidence interval (CI) ‐0.26 to 0.06; 614 participants; 8 studies). There was probably also little or no difference between groups after six to nine months (mean difference (MD) 0.59 point, 95% CI ‐1.12 to 2.3, 357 participants; 2 studies; moderate‐quality evidence). The evidence on response rates at 12 weeks was of low quality, and imprecision in the result meant we were uncertain of any effect of antidepressants (antidepressant: 49.1%, placebo: 37.7%; odds ratio (OR) 1.71, 95% CI 0.80 to 3.67; 116 participants; 3 studies). However, the remission rate was probably higher in the antidepressant group than the placebo group (antidepressant: 40%, placebo: 21.7%; OR 2.57, 95% CI 1.44 to 4.59; 240 participants; 4 studies; moderate‐quality evidence). The largest of these studies continued for another 12 weeks, but because of imprecision of the result we could not be sure of any effect of antidepressants on remission rates after 24 weeks. There was evidence of no effect of antidepressants on performance of activities of daily living at weeks 6 to 13 (SMD ‐0.05, 95% CI ‐0.36 to 0.25; 173 participants; 4 studies; high‐quality evidence) and probably also little or no effect on cognition (MD 0.33 point on the Mini‐Mental State Examination, 95% CI ‐1.31 to 1.96; 194 participants; 6 studies; moderate‐quality evidence). </p> <p>Participants on antidepressants were probably more likely to drop out of treatment than those on placebo over 6 to 13 weeks (OR 1.51, 95% CI 1.07 to 2.14; 836 participants; 9 studies). The meta‐analysis of the number of participants suffering at least one adverse event showed a significant difference in favour of placebo (antidepressant: 49.2%, placebo: 38.4%; OR 1.55, 95% CI 1.21 to 1.98, 1073 participants; 3 studies), as did the analyses for participants suffering one event of dry mouth (antidepressant: 19.6%, placebo: 13.3%; OR 1.80, 95% CI 1.23 to 2.63, 1044 participants; 5 studies), and one event of dizziness (antidepressant: 19.2%, placebo: 12.5%; OR 2.00, 95% CI 1.34 to 2.98, 1044 participants; 5 studies). Heterogeneity in the way adverse events were reported in studies presented a major difficulty for meta‐analysis, but there was some evidence that antidepressant treatment causes more adverse effects than placebo treatment does. </p> </section> <section id="CD003944-sec-0007"> <h3 class="title" id="CD003944-sec-0007">Authors' conclusions</h3> <p>The available evidence is of variable quality and does not provide strong support for the efficacy of antidepressants for treating depression in dementia, especially beyond 12 weeks. On the only measure of efficacy for which we had high‐quality evidence (depression rating scale scores), antidepressants showed little or no effect. The evidence on remission rates favoured antidepressants but was of moderate quality, so future research may find a different result. There was insufficient evidence to draw conclusions about individual antidepressant drugs or about subtypes of dementia or depression. There is some evidence that antidepressant treatment may cause adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003944-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003944-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003944-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003944-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003944-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003944-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003944-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003944-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003944-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003944-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003944-abs-0004" lang="en"> <h3>Antidepressants for treating depression in dementia</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect of antidepressants on depression in people with dementia. </p> <p><b>Background</b> </p> <p>Depression can be hard to recognise in people with dementia, but there is evidence that it is common and associated with increased disability, poorer quality of life, and shorter life expectancy. Many people with dementia are prescribed antidepressants to treat depression, but there is uncertainty about how effective this is. </p> <p>This review updates an earlier version, first published in 2002.</p> <p><b>Search date</b> </p> <p>We searched up to August 2017 for relevant studies.</p> <p><b>Study characteristics</b> </p> <p>We found ten studies with 1592 people to include in the review. On average, the studies lasted only 12 weeks, although one study ran for nine months. Each of them used a set of formal criteria to diagnose both depression and dementia and compared an antidepressant against a dummy pill (placebo). </p> <p>The older studies used more old‐fashioned antidepressants (imipramine, clomipramine, and moclobemide) and the newer studies used more modern ones, such as venlafaxine, mirtazapine and so‐called SSRI antidepressants (sertraline, fluoxetine, citalopram and escitalopram). </p> <p>The people taking part in the studies had an average age of 75 and they had mild or moderate dementia. With the exception of two studies, they were being treated as outpatients. </p> <p><b>Key results</b> </p> <p>We found that there was little or no difference in scores on depression rating scales between people treated with antidepressants and those treated with placebo for 12 weeks. The evidence to support this finding was of high quality, which suggests that further research is unlikely to find a different result. There was probably also little or no difference after six to nine months of treatment. </p> <p>Another way to assess the effect of antidepressants is to count the number of people in the antidepressant and placebo groups who show significant clinical improvement (response) or who recover from depression (remission). There was low‐quality evidence on the number of people showing a significant clinical improvement and the result was imprecise so we were unable to be sure of any effect on this measure. People taking an antidepressant were probably more likely to recover from depression than were those taking placebo (antidepressant: 40%, placebo: 21.7%). There was moderate‐quality evidence for this finding, so it is possible that further research could find a different result. </p> <p>We found that antidepressants did not affect the ability to manage daily activities and probably had little or no effect on a test of cognitive function (which includes attention, memory, and language). </p> <p>People taking an antidepressant were probably more likely to drop out of treatment and to have at least one unwanted side effect. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence varied, mainly due to poorly conducted studies and problems with the relevance of the outcome measures used. This should be taken into consideration when interpreting the different results on depression rating scales and recovery rates, as evidence was of a higher quality for the former than for the latter. </p> <p>Another major problem is that side effects are very rarely well‐reported in studies.</p> <p>Therefore, further research will still be useful to reach conclusions that are more reliable and can better help doctors and patients to know what works for whom. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003944-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003944-sec-0079">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003944-sec-0139">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003944-sec-0079"></div> <h3 class="title" id="CD003944-sec-0080">Implications for practice</h3> <section id="CD003944-sec-0080"> <p>Although depression is common in people with dementia and many patients are prescribed antidepressants, there is limited published evidence to support the efficacy of antidepressants for the treatment of depression in this patient group. They do not improve outcomes on depression rating scales, although there is moderate‐quality evidence to show that they probably increase short‐term remission rates. There is also moderate‐quality evidence that they are associated with more adverse effects than placebo. Although we did not find differential effects of different antidepressants, these subgroup data were sparse. It is possible that patients with different clinical characteristics (subtypes or severities or dementia or depression) may respond differently. </p> </section> <h3 class="title" id="CD003944-sec-0081">Implications for research</h3> <section id="CD003944-sec-0081"> <p>With an expanding ageing population and a resultant increase in the prevalence of dementia, more research is needed in this important clinical area. There is a need for well‐conducted randomised controlled trials, using scales validated in older people with depression and dementia (such as the Cornell Scale for Depression in Dementia), of modern, frequently used drugs and sufficient sample sizes that would allow a study of treatment response and detailed adverse event profile according to dementia aetiology and severity and depression severity. We would recommend that future research explores narrower spectra of cognitive impairment and more specific subsyndromes of affective disturbance in dementia. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003944-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003944-sec-0022"></div> <div class="table" id="CD003944-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antidepressant treatment compared with placebo for depression in dementia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antidepressant treatment compared with placebo for depression in dementia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with depression and dementia </p> <p><b>Settings:</b> outpatient (except Roth 1996, which was mixed in‐ and outpatients) </p> <p><b>Intervention:</b> antidepressant treatment </p> <p><b>Comparison:</b> placebo treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antidepressant</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression endpoint mean scores at 6 to 13 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised depression ratings scale endpoint mean score in the antidepressant group was <b>0.10 points lower</b> (0.26 lower to 0.06 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>614<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of an effect of antidepressants on depression in dementia</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of responders (ITT) at 6 to 12 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>509 per 1000</b> </p> <p>(326 to 690)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.71</b> (0.80 to 3.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of an effect of antidepressants regarding response to treatment for depression in dementia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with remission (ITT) at 6 to 12 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000‏</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>415 per 1000</b> </p> <p>(285 to 559)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.57</b> [1.44, 4.59] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of a positive effect of antidepressants on remission of depression in dementia</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function endpoint mean scores at 6 to 12 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The MMSE endpoint mean score in the antidepressant group was <b>0.33 points higher</b> [1.31 lower to 1.96 higher] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(194)<br/> (5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of an effect of antidepressants on cognitive function in patients with depression and dementia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living, endpoint values at 6 to 13 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean difference in ADL endpoint mean scores in the antidepressant group was <b>0.05 points lower</b> [0.36 lower to 0.25 higher] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of an effect of antidepressants on ADLs in patients with depression and dementia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of dropouts at 6 to 13 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>248 per 1000</b> </p> <p>(189 to 318)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.51</b> </p> <p>(1.07 to 2.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>836<br/> (9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of a negative effect of antidepressants on staying in treatment in patients with depression in dementia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients experiencing at least one adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>384 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b> </p> <p>(430 to 553)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.55</b> </p> <p>(1.21 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1073<br/> (5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of a negative effect of antidepressants related to side effects in patients with depression and dementia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Risk Ratio; <b>ITT:</b> intention‐to‐treat; <b>MMSE:</b> Mini–Mental State Examination </p> <p>A SMD of 0.2 is often considered to represent a small effect size, 0.5 a moderate effect size and 0.8 a large effect size. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different </p> <p><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect </p> <p><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The quality of the evidence was downgraded due to indirectness (the definitions of “response” were different in the studies and some could be considered surrogate measures, e.g. “best clinical judgement”) and imprecision (comparison was underpowered due to low number of total number of participants). </p> <p><sup>2</sup>The quality of the evidence was downgraded due to indirectness (the definitions of “remission” were different in the studies and some could be considered surrogate measures, e.g. “best clinical judgement”). </p> <p><sup>3</sup>The quality of the evidence was downgraded due to imprecision (relatively low number of participants and wide confidence intervals). </p> <p><sup>4</sup> The quality of the evidence was downgraded due to imprecision (the analysis is underpowered; also, the 95% CI around the pooled or best estimate of effect include both little effect and appreciable harm). </p> <p><sup>5</sup>The quality of evidence was downgraded due to selective reporting. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003944-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003944-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003944-sec-0100">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD003944-sec-0023"></div> <section id="CD003944-sec-0024"> <h3 class="title" id="CD003944-sec-0024">Description of the condition</h3> <p>People with dementia are commonly afflicted with depression (<a href="./references#CD003944-bbs2-0063" title="BennettS , ThomasA . Depression and dementia: cause, consequence orcoincidence?. Maturitas2014;79(2):184‐90. ">Bennet 2014</a>; <a href="./references#CD003944-bbs2-0080" title="LeyheT , ReynoldsCF3rd , MelcherT , LinnemannC , KlöppelS , BlennowK , et al. A common challenge in older adults:classification, overlap, and therapy of depression and dementia. Alzheimer’s &amp; Dementia2017;13(1):59‐71. ">Leyhe 2017</a>) and depression is associated with increased disability, impaired quality of life, and higher mortality (<a href="./references#CD003944-bbs2-0064" title="BlackBS , JohnstonD , MorrisonA , RabinsPV , LyketsosCG , SamusQM . Quality of life of community‐residing persons with dementia based on self‐rated andcaregiver‐rated measures. Quality of Life Research2012;21(8):1379‐89. ">Black 2012</a>; <a href="./references#CD003944-bbs2-0067" title="DinizBS , ButtersMA , AlbertSM , DewMA , ReynoldsCF3rd . Late‐life depressionand risk of vascular dementia and Alzheimer's disease: systematic review andmeta‐analysis of community‐based cohort studies. British Journal of Psychiatry2013;202(5):329‐35. ">Diniz 2013</a>; <a href="./references#CD003944-bbs2-0100" title="VaughanL , CorbinAL , GoveasJS . Depression and frailty in later life: a systematic review. Clinical Interventions in Aging2015;10:1947‐58. ">Vaughan 2015</a>). </p> <p>However, both depression and dementia are concepts with nebulous boundaries. Depressive illness has been conceptualised in dimensional and categorical terms with no consensus about its fundamental nature. When conceptualised dimensionally, depression's various presentations are explained by their position on a continuum of increasing severity. When conceptualised categorically, depressive illness is sub‐grouped into discrete entities such as melancholic or non‐melancholic depression and anxious depression (<a href="./references#CD003944-bbs2-0090" title="ParkerG . Should paradigms lost be regained?. American Journal of Psychiatry2000;157:1195‐203. ">Parker 2000</a>). Dementia is a syndrome that may arise from a variety of underlying pathologies, the most common of which are Alzheimer's disease, vascular dementia, and dementia with Lewy bodies. </p> <p>Given the complex nature of both depression and dementia, understanding the relationship between the two is difficult. Depressive illness in older people can present as 'pseudodementia' and be difficult to distinguish from a dementing illness (<a href="./references#CD003944-bbs2-0092" title="RaskindMA . The clinical interface of depression and dementia. Journal of Clinical Psychiatry1998;59(Suppl 10):9‐12. ">Raskind 1998</a>). On the other hand, depression is often associated with deterioration in cognitive functioning which is sometimes not completely reversible with treatment (<a href="./references#CD003944-bbs2-0057" title="AbasMA , SahakianBJ , LevyR . Neuropsychological deficits and CT scan changes in elderly depressives. Psychological Medicine1990;20:507‐20. ">Abas 1990</a>). Moreover, in older people a history of depression in later life may be associated with an increased risk of subsequently developing a dementing illness (<a href="./references#CD003944-bbs2-0085" title="NaismithSL , NorrieLM , MowszowskiL , HickieIB . Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology2010;75:27‐34. ">Naismith 2010</a>; <a href="./references#CD003944-bbs2-0066" title="ByersAL , YaffeK . Depression and risk of developing dementia. Nature Reviews Neurology2011;7(6):323–31. ">Byers 2011</a>; <a href="./references#CD003944-bbs2-0062" title="BarnesDE , YaffeK , ByersAL , McCormickM , SchaeferC , WhitmerRA . Midlife vs late‐life depressive symptoms and risk of dementia: differential effects for Alzheimer Disease and vascular dementia. Archives of General Psychiatry2012;69(5):493‐8. ">Barnes 2012</a>; <a href="./references#CD003944-bbs2-0076" title="HeserK , TebarthF , WieseB , EiseleM , BickelH , KöhlerM , et al. Age of major depression onset, depressivesymptoms, and risk for subsequent dementia: results of the German study onAgeing, Cognition, and Dementia in Primary Care Patients (AgeCoDe). Psychological Medicine2013;43(8):1597‐610. ">Heser 2013</a>; <a href="./references#CD003944-bbs2-0067" title="DinizBS , ButtersMA , AlbertSM , DewMA , ReynoldsCF3rd . Late‐life depressionand risk of vascular dementia and Alzheimer's disease: systematic review andmeta‐analysis of community‐based cohort studies. British Journal of Psychiatry2013;202(5):329‐35. ">Diniz 2013</a>). Both disorders are common in older people and may therefore be expected to occur together solely by chance. </p> <p>Because of these complexities, diagnosing depression in patients with dementia can be difficult. Denial and cognitive impairment may compromise self‐report of depressive symptoms by people with dementia. As the dementing illness progresses, the presentation of depression may alter, with non‐verbal manifestations (e.g. demanding behaviour, clinging) being more apparent than cognitive features (<a href="./references#CD003944-bbs2-0101" title="VidaS , DesRosiersP , CarrierL , et al. Prevalence of depression in Alzheimer's disease and validity or research diagnostic criteria. Journal of Geriatric Psychiatry and Neurology1994;7:238‐44. ">Vida 1994</a>). Moreover, neurovegetative (autonomic) symptoms such as poor concentration and anhedonia (reduction in or complete lack of ability to enjoy activities the person usually finds enjoyable) are features of both depression and dementia. Not surprisingly, there is no consensus on how best to diagnose depression in demented patients. Depression symptom scales may overestimate, whereas structured diagnostic interviews may underestimate, the prevalence of depression in people with dementia. Only one instrument — the Cornell Scale for Depression in Dementia (CSDD, <a href="./references#CD003944-bbs2-0058" title="AlexopoulosGS , AbramsRC , YoungRC , ShamoianCA . Cornell Scale for Depression in Dementia. Biological Psychiatry1988;23(3):271‐84. ">Alexopoulos 1988</a>) — has been specifically developed for use in a population with dementia. Given the complexity of the issues impinging on accurate diagnosis, it is not surprising that estimates of the incidence and prevalence rates of depression in patients with dementia vary between 0% and 86%. Larger studies using standardised criteria for major depressive disorder in Alzheimer's disease provide estimates of prevalence at 10% to 20% (<a href="./references#CD003944-bbs2-0081" title="LoreckDJ , FolsteinMF . Depression in Alzheimer Disease. In: StarksteinSE , RobinsonRG editor(s). Depression in Neurologic Disease. The John Hopkins series in pyschiatry and neuroscience. Baltimore, MD, US: John Hopkins University Press, 1993:50‐62. ">Loreck 1993</a>). </p> </section> <section id="CD003944-sec-0025"> <h3 class="title" id="CD003944-sec-0025">Description of the intervention</h3> <p>Drugs licensed as antidepressants are a heterogeneous group. They are commonly described as falling into a number of classes with different mechanisms of action, although the various classes are generally reported to be of similar efficacy (<a href="./references#CD003944-bbs2-0060" title="AndersonIM . Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta‐analysis of efficacy and tolerability. Journal of Affective Disorders2000;58:19‐36. ">Anderson 2000</a>; <a href="./references#CD003944-bbs2-0104" title="WilliamsJWJr , MulrowCD , ChiquetteE , NoelPH , AguilarC , CornellJ . A systematic review of newer pharmacotherapies for depression in adults: evidence report summary: Clinical Guidelines, Part 2. Annals of Internal Medicine2000;132:743‐56. ">Williams 2000</a>). However, different drugs or classes of drugs may vary in their efficacy or safety in the depression of dementia, or may be preferentially effective in particular subtypes of dementia. </p> <p>The oldest class of antidepressants is the tricyclic antidepressants (TCAs), including drugs such as amitriptyline, imipramine, clomipramine and nortriptyline. As a class, they are associated with side effects that are potentially more problematic for older than for younger patients. In particular, their anticholinergic properties are associated with a negative impact on cognition (<a href="./references#CD003944-bbs2-0096" title="SettleECJr . Antidepressant drugs: disturbing and dangerous adverse events. Journal of Clinical Psychiatry1998;59(Suppl 16):25‐30. ">Settle Jr 1998</a>). Other problematic anticholinergic effects would include increased intra‐ocular pressure, urinary retention, dry mouth, and constipation. Due to their anti‐adrenergic side effects, they can also cause postural hypotension (<a href="./references#CD003944-bbs2-0071" title="GlassmanAH , BiggerJTJr . Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review. Archives of General Psychiatry1981;38:815‐20. ">Glassman 1981</a>), and dizziness, thereby increasing the risk of falls. A second class of antidepressants, the selective serotonin reuptake inhibitors (SSRIs), is now more widely used for older people. SSRIs include fluoxetine, paroxetine, sertraline, citalopram, and escitalopram. These drugs have a different range of side effects, most notably nausea and vomiting, agitation, anxiety, indigestion, diarrhoea or constipation, loss of appetite and weight loss, dizziness, blurred vision, dry mouth, excessive sweating, insomnia or drowsiness, headaches, and sexual side effects. However, they have less marked anticholinergic and anti‐adrenergic properties and therefore may be less likely to cause confusion or falls (<a href="https://archie.cochrane.org/sections/documents/view?version=z1503291142077609500455715305071%26format=REVMAN#REF-Avorn-1998" target="_blank">Avorn 1998</a>). Other antidepressant drug classes include selective serotonergic and noradrenergic reuptake inhibitors (SNRIs) such as venlafaxine and duloxetine, tetracyclic anti‐depressants such as trazodone and maprotiline, and the reversible monoamine oxidase inhibitors (MAOIs), such as moclobemide. Another often used example of the newer antidepressants is the alpha2‐antagonist mirtazapine<i>.</i> </p> </section> <section id="CD003944-sec-0026"> <h3 class="title" id="CD003944-sec-0026">Why it is important to do this review</h3> <p>Dementia with depression is a common and important clinical problem. A recent Cochrane Review of psychological treatments for depression in dementia found evidence for benefit, but it was poor‐quality, heterogeneous evidence (<a href="./references#CD003944-bbs2-0088" title="OrgetaV , QaziA , SpectorAE , OrrellM . Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD009125.pub2] ">Orgeta 2014</a>). The use of antidepressants for patients with dementia accompanied by depressive symptoms is widespread, but their clinical efficacy is uncertain. This uncertainty is due in part to the difficulties of interpreting the results of clinical trials. Many of the individual trials of antidepressants have been too small to provide precise estimates of the benefits that might realistically be expected. Combining the information from all appropriate trials may provide a better estimate of the likely effects of treatment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003944-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003944-sec-0027">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003944-sec-0104">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003944-sec-0027"></div> <p>To determine the efficacy and safety of any type of antidepressant for patients who have been diagnosed as having dementia of any type and depression as defined by recognised criteria. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003944-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003944-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003944-sec-0105">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003944-sec-0028"></div> <section id="CD003944-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003944-sec-0030"> <h4 class="title">Types of studies</h4> <p>We considered all identified relevant double‐blind, randomised, placebo‐controlled trials of longer than four weeks' duration. Trials in which the allocation to treatment or placebo was not random, or in which treatment allocation was not concealed, were excluded (<a href="./references#CD003944-bbs2-0059" title="AltmanDG , BlandJM . Treatment allocation in controlled trials: why randomise?. BMJ1999;318:1209. ">Altman 1999</a>). </p> </section> <section id="CD003944-sec-0031"> <h4 class="title">Types of participants</h4> <section id="CD003944-sec-0032"> <h5 class="title">Inclusion criteria</h5> <p>To ensure participants of included trials were comparable, subjects were required to meet accepted diagnostic criteria. We included trials involving participants with dementia as diagnosed by accepted criteria such as DSM (<a href="./references#CD003944-bbs2-0061" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington: APA, 1987. ">APA 1987</a>), NINCDS‐ADRDA (<a href="./references#CD003944-bbs2-0082" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>) and ICD‐10 (<a href="./references#CD003944-bbs2-0102" title="World Health Organization. International Classification of Disease (ICD‐10). Geneva: WHO, 1992. ">WHO 1992</a>), with a coexisting depressive illness as diagnosed by similarly accepted criteria. Participants could be of either sex and of any age. </p> </section> <section id="CD003944-sec-0033"> <h5 class="title">Exclusion criteria</h5> <p>We excluded studies of patients with dementia suffering from emotional disorders or behavioural problems, but falling short of a diagnosis of depression (as diagnosed by recognised criteria). </p> </section> </section> <section id="CD003944-sec-0034"> <h4 class="title">Types of interventions</h4> <section id="CD003944-sec-0035"> <h5 class="title">Inclusion criteria</h5> <p>Any antidepressant medication listed in the British National Formulary number 73, 2017 (see <a href="#CD003944-sec-0041">Electronic searches</a> for list of antidepressants) compared with placebo. There was no minimum dose requirement for inclusion. </p> </section> <section id="CD003944-sec-0036"> <h5 class="title">Exclusion criteria</h5> <p>We excluded trials of euphoriants (e.g. amphetamines), adjuvants (e.g. lithium), combination treatments (e.g. 'Motipres'), studies of other drug classes not generally regarded primarily as antidepressants (e.g. antipsychotics), and agomelatine, which is contra‐indicated in dementia. </p> </section> </section> <section id="CD003944-sec-0037"> <h4 class="title">Types of outcome measures</h4> <p>The outcomes of interest were as follows (<a href="#CD003944-tbl-0002">Table 1</a> summarises the outcome measures analysed in this paper). </p> <div class="table" id="CD003944-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome measures</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Abbreviation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Brief description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Used in</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><i>Depression rating scales</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hamilton Depression Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HAMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0075" title="Hamilton , M . A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry1960;23:56‐62. ">Hamilton 1960</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>depressive symptom levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinician‐rated, multiple choice rating scale of depressive symptom severity designed to be sensitive to change with treatment in the general adult population. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a>, <a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>, <a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>, <a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cornell Scale for Depression in Dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0058" title="AlexopoulosGS , AbramsRC , YoungRC , ShamoianCA . Cornell Scale for Depression in Dementia. Biological Psychiatry1988;23(3):271‐84. ">Alexopoulos 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>depressive symptom levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For the diagnosis of depression in patients with a dementia syndrome administered by a clinician. It takes 20 minutes with the carer and 10 minutes with the patient. The scale has 19 items, rated on a 3 point scale: absent, mild or intermittent and severe, based on the week prior to the interview. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>, <a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a><a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>, </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Montgomery Asberg Depression Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MADRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0084" title="MontgomerySA , ÅsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382‐89. ">Montgomery 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>depressive symptom levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A 10‐item clinician‐rated diagnostic questionnaire to measure the severity of depressive symptomatology in mood disorders. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geriatric Depression Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0105" title="YesavageJA , BrinkTL , RoseTL , et al. Development and validation of a geriatric depression screening scale: a preliminary report. Journal of Psychiatric Research1982;17(1):37‐49. ">Yesavage 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>depressive symptom levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A 30‐item, self‐report assessment used to identify depression in the elderly. The simple response format (yes/no questions) makes it more suitable for use in those with cognitive impairment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><i>Cognitive measure</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mini‐mental State Examination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0069" title='FolsteinMF , FolsteinSE , McHughPR . "Mini‐mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12(3):189‐98. '>Folstein 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>level of cognitive functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A 30‐point clinician‐administered cognitive test for cognitive impairment, assessing orientation, concentration, memory, language, and visuo‐spatial function. Higher scores indicate better functioning. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All included studies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><i>Activities of daily living</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Psychogeriatric dependency rating scales ‐ ADL subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PGDRS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0103" title="WilkinsonIM , Graham‐White , J . Psychogeriatric dependency rating scales (PGDRS): a method of assessment for use by nurses. British Journal of Psychiatry1980;137:558‐65. ">Wilkinson 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>need for assistance with functional abilities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physical capacity consists of 7 sub‐categories. Higher scores indicate more disability.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADCS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0070" title="GalaskoD , BennettD , SanoM , et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Disease and Associated Disorders1997;11(suppl 2):33S‐39S. ">Galasko 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>functional ability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Informant‐based, last 4 weeks. Higher score indicates better performance.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Functional Independence Measure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FIM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0072" title="GrangerCV , HamiltonBB , KaytonR . Functional Independence Measure. Guide for use of the uniform data set for medical rehabilitation. Buffalo, NY: Uniform Data System for Medical Rehabilitation, 1986. ">Granger 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>need for assistance with functional abilities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 items on self‐care, sphincter control, mobility, locomotion, communication, social cognition. Higher scores indicate more disability. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>, <a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older American Resources and Services</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OARS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0091" title="PfeifferE . Multidimensional functional assessment: The OARS methodology. Durham, North Carolina: Center for the Study of Aging and Human Development1975. ">Pfeiffer 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>functional ability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An 14‐item assessment for physical function, including bathing, dressing, grooming, and continence, relying on self report. Higher scores indicate better functioning. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seoul‐Instrumental Activities of Daily Living</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0078" title="KuHM , KimJH , KwonEJ , KimSH , LeeHS , KoHJ , et al. A Study on the Reliability and Validity of Seoul‐Instrumental Activities of Daily Living(S‐IADL). Journal of Korean Neuropsychiatric Association2004;43(2):189‐99. ">Ku 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>instrumental everyday activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A 15‐item instrument to assess complex functions of daily living, with a total score from 0 to 45. Higher scores reflect worse function. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a> </p> </td> </tr> </tbody> </table> </div> <section id="CD003944-sec-0038"> <h5 class="title">Primary outcomes</h5> <p>Effect on depression (measured by rating scales, and by rates of response or remission defined according to clear criteria). </p> </section> <section id="CD003944-sec-0039"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD003944-list-0001"> <li> <p>Effect on cognitive function (measured by validated psychometric tests).</p> </li> <li> <p>Effect on activities of daily living (measured by validated rating scales).</p> </li> <li> <p>Effect on quality of life (measured by validated rating instruments).</p> </li> <li> <p>Tolerability (measured by withdrawal from trial).</p> </li> <li> <p>Safety (measured by the incidence of adverse effects).</p> </li> </ol> </p> </section> </section> </section> <section id="CD003944-sec-0040"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003944-sec-0041"> <h4 class="title">Electronic searches</h4> <p>We searched ALOIS (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>), the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register on 16 August 2017. The search was done on a tag used in ALOIS for studies in which the following antidepressant terms have been used: antidepressant, amitriptyline, lentizol, tryptizol, triptafen, amoxapine, asendis, clomipramine, anafranil, dothiepin, perothiaden, doxepin, sinequan, imipramine, tofranil, lofepramine, gamanil, nortriptyline, allegron, protriptyline, concordin, trimipramine, surmontil, maprotiline, ludiomil, mianserin, mirtazapine, zispin, trazodone, molipaxin, viloxazine, vivalan, phenelzine, nardil, isocarboxazid, tranylcypromine, parnate, moclobemide, manerix, fluoxetine, prozac, citalopram, cipramil, fluvoxamine, faverin, paroxetine, seroxat, sertraline, lustral, nefazadone, dutonin, venlafaxine, efexor, flupenthixol, depixol, fluanxol, reboxetine, edronax, tryptophan, optimax, escitalopram, cipralex, dosulepin, dothapex, prepadine, and vortioxetine. </p> <p>ALOIS is maintained by the Information Specialist for the Cochrane Dementia and Cognitive Improvement Group and contains studies in the areas of dementia prevention, dementia treatment and cognitive enhancement in the healthy. The studies are identified from:   </p> <p> <ol id="CD003944-list-0002"> <li> <p>monthly searches of a number of major healthcare databases: MEDLINE, Embase, Cinahl, PsycINFO and Lilacs; </p> </li> <li> <p>monthly searches of a number of trial registers: UMIN (Japan's Trial Register); ICTRP/the WHO portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others); </p> </li> <li> <p>quarterly search of the Cochrane Library’s Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>six‐monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses; Australasian Digital Theses. </p> </li> </ol> </p> <p>To view a list of all sources searched for ALOIS, see <a href="http://www.medicine.ox.ac.uk/alois/content/about-alois" target="_blank">About ALOIS</a> on the ALOIS website. </p> <p>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the ‘methods used in reviews’ section within the editorial information about the <a href="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html" target="_blank">Dementia and Cognitive Improvement Group</a>. </p> <p>Additional searches were performed in many of the sources listed above to cover the timeframe from the last searches performed for ALOIS to ensure that the search for the review was as up‐to‐date and as comprehensive as possible. The search strategies used can be seen in <a href="./appendices#CD003944-sec-0085">Appendix 1</a>. </p> </section> <section id="CD003944-sec-0042"> <h4 class="title">Searching other resources</h4> <p>We consulted a number of experts in old age psychiatry. We also asked the medical information departments of major pharmaceutical companies to search databases and their records for trials involving their products. In addition, we searched reference lists of retrieved studies and review articles. </p> </section> </section> <section id="CD003944-sec-0043"> <h3 class="title" id="CD003944-sec-0043">Data collection and analysis</h3> <section id="CD003944-sec-0044"> <h4 class="title">Selection of studies</h4> <p>A single review author (for the first edition: JB [see <a href="#CD003944-sec-0089">Contributions of authors</a> for full names], for the current revision: RD) discarded irrelevant citations identified by searches, based on the title of the publication and its abstract. If there was any suggestion that an article could be relevant, it was retrieved for further assessment. Two review authors (first edition: JB and JSB, current revision: RD and TD) then independently selected the trials for inclusion in the review from the culled citation list. </p> </section> <section id="CD003944-sec-0045"> <h4 class="title">Data extraction and management</h4> <p>For the original review, data were independently extracted by two review authors (JB, JSB) and cross‐checked. Any discrepancies were discussed and adjudicated by a third reviewer (TD). For the current revision, data were extracted by the first author (RD). Data were sought on every participant for each outcome measure. To allow an intention‐to‐treat analysis, we sought data irrespective of compliance, whether or not the participant was subsequently deemed ineligible, or otherwise excluded from treatment or follow‐up. </p> <p>If ordinal scale data appeared to be approximately normally distributed, or if the analysis that the investigators performed suggested that parametric tests were appropriate, then we treated the outcome measures as continuous data. Where the outcome measure was a continuous variable or ordinal variable (such as psychometric test scores, clinical global impression scales, functional and quality of life scales) we extracted summary statistics, including means, standard deviations (SDs) and number in each treatment group, for the final assessment score (corrected for baseline) and the change in score from baseline (i.e. pre‐randomisation or randomisation) to the final assessment for each study. For dichotomous outcomes, the statistics extracted from each study were the numbers in each treatment group and the numbers in each endpoint category for each treatment group. Where dichotomous data were missing, the participants were assumed to have suffered the least favourable outcome. In studies where a cross‐over design was used, only data from the first treatment period were included. </p> <p>If trial results were reported as medians and interquartile ranges, we calculated SDs using the interquartile range (IQR) to provide the appropriate data to combine the study with other studies. </p> <p>When two different antidepressants were compared against placebo (<a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>), we divided the control group where relevant into two groups approximately evenly among the comparisons, with the means and SDs left unchanged. Where it was the only option, we merged the two treatment groups into one (antidepressant efficacy at three to nine months). </p> </section> <section id="CD003944-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed included trials for risk of bias using the tool in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i>, version 5.1.0 (<a href="./references#CD003944-bbs2-0077" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration 2011 [updated March 2011]:www.cochrane‐handbook.org. ">Higgins 2011</a>). We judged whether each trial was at high, low or unclear risk of bias in each of six domains: sequence generation, concealment of allocation, blinding, completeness of outcome data, selective reporting, and funding source<i>.</i> </p> </section> <section id="CD003944-sec-0047"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcome data, we calculated the odds ratio for each trial, and then a pooled odds ratio across appropriate groups of trials (using Mantel‐Haenszel methods). For continuous variables, we calculated the mean difference between treatment and control when each study in the meta‐analysis used the same outcome measure, or the standardised mean difference when the studies used a variety of outcome measures. We used hazard ratios for time‐to‐event data. </p> </section> <section id="CD003944-sec-0048"> <h4 class="title">Unit of analysis issues</h4> <p>If a trial included multiple treatment groups, then we combined active treatment groups into one group and control treatment groups into one group to allow a single pairwise comparison. </p> <p>Some studies assessed outcomes at multiple time points, so we pooled data in ranges (e.g. 6 to 13 weeks and 3 to 9 months) to achieve the best match of time points when combining results with similar data from different studies. </p> </section> <section id="CD003944-sec-0049"> <h4 class="title">Dealing with missing data</h4> <p>For each study, we noted what approach had been taken to missing data, e.g. imputation, data assumed to be missing at random. We considered how each method may have contributed to a risk of bias. We contacted authors of extracted papers for clarification as required. </p> </section> <section id="CD003944-sec-0050"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested for heterogeneity of the treatment effect between the trials in a meta‐analysis using the Chi<sup>2</sup> statistic. We quantified inconsistency using I<sup>2</sup> and considered that an I<sup>2</sup> value of more than 40% might represent moderate heterogeneity. </p> </section> <section id="CD003944-sec-0051"> <h4 class="title">Assessment of reporting biases</h4> <p>If we had been able to include more than 10 studies in any meta‐analysis, then we would have performed a test for funnel plot asymmetry, looking for small study effects which might indicate publication bias. </p> </section> <section id="CD003944-sec-0052"> <h4 class="title">Data synthesis</h4> <p>We pooled data from different trials if we considered that the trials were sufficiently similar and it was clinically meaningful to do so. In our primary analyses, we pooled trials of all dementia subtypes and all types of antidepressants. We also preformed a separate analysis of antidepressant efficacy at six to nine months. </p> <p>For dichotomous efficacy outcomes, we used the Mantel‐Haenszel method, as the study sizes were small. For our tolerability outcomes, we used the Peto odds ratio method, as for these outcomes we had larger samples, the intervention effects were relatively small, and the events were not particularly common. If a Chi<sup>2</sup> test and I<sup>2</sup> indicated little heterogeneity, we used a fixed‐effect model for meta‐analysis. If there was evidence of heterogeneity of the treatment effect between trials, we either pooled only homogeneous results, or used a random‐effects model (in which case the confidence intervals would be broader than those of a fixed‐effect model). </p> <p>When combining data provided as median and 95% confidence interval (CI), we used the generic inverse variance method. We used standard error and median difference. </p> </section> <section id="CD003944-sec-0053"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Five of the included studies used an SSRI antidepressant (<a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>; <a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>; <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>; <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>; <a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a>), one mirtazapine (<a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>), and one venlafaxine (<a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a>). These are more modern antidepressants commonly used in this patient group (as opposed to tricyclic antidepressants), so we performed a meta‐analysis on these subgroups. Where it made clinical sense (e.g. when examining tolerability), we also looked at data by antidepressant group, where possible. </p> </section> <section id="CD003944-sec-0054"> <h4 class="title">Sensitivity analysis</h4> <p>When looking at treatment efficacy as reflected by depression symptom rating scale scores, we also performed a sensitivity analysis only looking at studies that used the Cornell Scale for Depression in Dementia (<a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>; <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>; <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>; <a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a>), an instrument specifically developed to measure depressive symptoms in dementia. As in our main treatment efficacy comparison, some studies only reported completer data, so we carried out a sensitivity analysis looking at intention‐to‐treat data only. We also performed a sensitivity analysis when the majority of individual studies reported results pointing toward the opposite of the result of the meta‐analysis, or when excluding a study was considered to reduce imprecision or inconsistency. </p> <section id="CD003944-sec-0055"> <h5 class="title">Summary of findings</h5> <p>We used the GRADE system to assess the overall quality of evidence behind the effect estimates for each outcome (<a href="./references#CD003944-bbs2-0093" title="RyanR , HillS . How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group. Version 1.0. Vol. http://cccrg.cochrane.org/author‐resources, Cochrane Consumers and Communication Group, June 2016. ">Ryan 2016</a>). We downgraded the evidence from 'high‐quality' by one, two, or three levels after considering imprecision in the effect estimate, risk of bias in the included studies, inconsistency between studies, indirectness of evidence, and publication bias. Two review authors (RD and TD) assessed the quality of evidence independently and resolved any disagreements. </p> <p>We presented the amount and quality of evidence in a 'Summary of findings' table for the following outcomes: depression (symptom score), depression (response rate), depression (remission rate), cognitive function, activities of daily living, dropout rate and incidence of adverse events. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003944-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003944-sec-0056"></div> <section id="CD003944-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD003944-sec-0058"> <h4 class="title">Results of the search</h4> <p>Searches carried out in the previous version of the review can be viewed in <a href="./appendices#CD003944-sec-0086">Appendix 2</a>. </p> <p>The searches performed for this update, run in November 2010, May 2012, March 2013, December 2013, March 2014, November 2014, October 2015, July 2016, and August 2017 retrieved a total of 827, 1233, 456, 495, 599, 620, 520, 859, and 1304 results, respectively (<a href="#CD003944-fig-0001">Figure 1</a>). The Information Specialist performed a first assessment to discard obviously non‐relevant records and duplicates. This left the author team with 43 (November 2010), 49 (May 2012), 27 (March 2013), 36 (December 2013), 31 (November 2014), 22 (October 2015), 40 (July 2016), and 60 (August 2017) results to further assess, from the last two rounds of which three additional trials were identified (DIADS, <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>, and <a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a>). </p> <div class="figure" id="CD003944-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003944-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003944-sec-0059"> <h4 class="title">Included studies</h4> <p>See: Characteristics of included studies (<a href="#CD003944-tbl-0003">Table 2</a>). </p> <div class="table" id="CD003944-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics and diagnostic criteria ‐ included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>dementia criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>depression criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>number of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean depression rating scale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NINCDS‐ADRDA for AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>three or more from Olin's criteria for depression in AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 mg/day of escitalopram, increased 5 mg/day every two weeks, up to a maximum dosage of 15 mg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.2 (6.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSDD: 11.39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NINCDS‐ADRDA for probable or possible AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>depression ≥ 4 weeks's duration potentially needing antidepressants; CSDD ≥ 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sertraline 70 mg/d (target dose: 150 mg/d), mirtazapine 24 mg/d (target dose: 45 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSDD: 12.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐IV for dementia (AD, VD, and mixed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐IV major depressive disorder and CSDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>venlafaxine (37.5‐131.25 mg/d, mean = 75 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.6 (6.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(range: 10‐24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MADRS: 24.5 (7.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III‐R for PDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III‐R 290.21(mildly depressed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>maprotiline (25 mg titrated to 75 mg/d, mean max. dose 59 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (48‐96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.4 (0‐30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS (median): 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NINCDS‐ADRDA for probable AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐VI for major depressive episode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sertraline (25 mg titrated to 150 mg/d, mean peak dose 113 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ham‐D: 22.75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NINCDS‐ADRDA for probable AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III‐R for dysthymia or major depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks + 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clomipramine (25 mg titrated to 100 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 (7.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.5 (6.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ham‐D:17.5 (6.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NINCDS‐ADRDA for probable AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐IV criteria for either major or minor depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluoxetine (10 mg titrated to 40 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ham‐D: 16.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III for PDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III (major depressive disorder)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>imipramine (mean dose 83 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.5 (5.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ham‐D: 18.9 (3.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐IV for AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criteria for depression of AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sertraline 50 mg/d increased to 100 mg/d, mean = 93.1 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.3 (8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 (4.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSDD (median): 13 (1st and 3rd quartile: 9, 18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III for dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III for major depressive episode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moclobemide (400 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.4 (8.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.2 (4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.5 (5.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a> </p> <p>(extension of <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐IV for AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criteria for depression of AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>randomised treatment with sertraline for at least partial responders after week 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.3 (8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 (4.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSDD (median): 13 (1st and 3rd quartile: 9, 18)</p> </td> </tr> </tbody> </table> </div> <p>Ten studies with a total of 1592 participants met the inclusion criteria. The studies were generally of short duration (mode: 6 weeks; mean: 12.7 weeks), although the largest study ran for nearly 10 months (<a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>). The findings from one study (DIADS‐2) were reported in separate publications, giving results at 12 weeks (<a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>), and also after an extension phase at 24 weeks (<a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a>). </p> <p>All 10 studies stated that the participants met DSM criteria for dementia or NINCDS‐ADRDA criteria for probable Alzheimer's disease. The dementia diagnoses in the trial participants were described in a variety of ways: </p> <p> <ol id="CD003944-list-0003"> <li> <p><a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a>: "Alzheimer's disease"; </p> </li> <li> <p><a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>: "probable Alzheimer's disease"; </p> </li> <li> <p><a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a>: "Alzheimer's disease, vascular dementia, and mixed dementia"; </p> </li> <li> <p>DIADS‐2 (<a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a> and <a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a>): "DSM‐IV dementia due to Alzheimer's disease"; </p> </li> <li> <p><a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a>: "primary degenerative dementia"; </p> </li> <li> <p><a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>: "probable Alzheimer's disease"; </p> </li> <li> <p><a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>: "Alzheimer's disease"; </p> </li> <li> <p><a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>: "probable Alzheimer's disease"; </p> </li> <li> <p><a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a>: "primary degenerative dementia of the Alzheimer's type"; </p> </li> <li> <p><a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a>: "dementia". </p> </li> </ol> </p> <p>The mean age of participants who met inclusion criteria in the studies, excluding one study which only reported the median age of 80 years (<a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a>), was between 70.8 and 79.3 years, with an overall mean of 75.37 years. </p> <p>One Austrian study was conducted among inpatients and nursing home residents (<a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a>). One multinational study included both inpatients and outpatients (<a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a>). The other studies were conducted in single countries and included only outpatients. The outpatient settings varied, including neurology outpatient clinics in Argentina, specialist memory and other outpatient clinics in the USA and Brazil, and community mental health teams in the UK. </p> <p>The severity of dementia in the studies varied. The mean Mini Mental State Examination (MMSE) score prior to treatment in those participants who met inclusion criteria for the review was between 16.9 to 23.2 (mean score 19.65). One study, <a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a>, only reported a range of MMSE scores of 10 to 24, and another, <a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a>, reported a median of 20 and no mean scores. </p> <p>Six studies stated that the participants met DSM criteria for major depression, with one study stating subjects met DSM criteria for either major or minor depression (<a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>). One study required the presence of depression of at least four weeks' duration, assessed as potentially needing antidepressants and scoring eight or more on the Cornell Scale for Depression in Dementia (CSDD), prior to inclusion (<a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>). In most studies, participants were diagnosed clinically, whereas two studies used a structured clinical interview schedule (<a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>; <a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>). The DIADS‐2 study used specifically adapted <a href="https://jhuccs1.us/diads2/pdf%20forms/md1.pdf" target="_blank">Major Depression Criteria</a>. The papers reporting on this study (<a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>; <a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a>), do not provide validity data regarding the Major Depression Criteria, but a relevant study, <a href="./references#CD003944-bbs2-0098" title="TengE , RingmanJM , RossLK , MulnardRA , DickMB , BartzokisG , et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. American Journal of Geriatric Psychiatry2008;16(6):469‐77. ">Teng 2008</a>, reported for the criteria set 100% sensitivity and 66% specificity for major and 94% sensitivity and 85% specificity for minor depression, measured against the DSM‐IV diagnosis, which is acceptable. </p> <p>The older studies used tricyclic antidepressants (TCAs) or related compounds; four used a selective serotonin reuptake inhibitor (SSRI); one used a reversible monoamine oxidase inhibitor; and one a serotonin/noradrenaline reuptake inhibitor. One study had two active treatment arms, an SSRI and a noradrenergic and specific serotonergic antidepressant (NaSSA) one (<a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>). The doses used in seven studies were within the therapeutic range for the specific medication. However, three studies used lower dose medication (<a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a>; <a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a>; <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>, for mirtazapine). </p> <p>The studies used a variety of outcome measures. Four studies used the Hamilton Depression Rating Scale, and four used the more specific Cornell Scale for Depression in Dementia to measure changes in depression symptom levels after treatment. One study used the Montgomery‐Asberg Depression Rating Scale and another used the Geriatric Depression Scale. All included studies used the Mini‐Mental State Examination to assess changes in cognitive functioning. Only five studies deployed one of four different standardised measures of activities of daily living. </p> <p><a href="#CD003944-tbl-0002">Table 1</a> summarises the outcome measures included in this review. </p> </section> <section id="CD003944-sec-0060"> <h4 class="title">Excluded studies</h4> <p>We excluded studies identified by the searches if their subjects did not have both depression and dementia diagnosed by formal criteria, the intervention was not an antidepressant or it was given in combination with another drug, the study was not a treatment trial or a randomised controlled trial, or change in depression was not measured. </p> <section id="CD003944-sec-0061"> <h5 class="title">Ongoing studies</h5> <p>We are not aware of any ongoing studies.</p> </section> </section> </section> <section id="CD003944-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>See our 'Risk of bias' assessment of included studies in <a href="#CD003944-fig-0002">Figure 2</a> and <a href="#CD003944-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD003944-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003944-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD003944-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003944-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>Two studies gave adequate descriptions of the randomisation method and allocation concealment and we judged them to be at low risk of bias in both of these domains (<a href="https://archie.cochrane.org/sections/documents/view?version=z1503291142077609500455715305071%26format=REVMAN#STD-Lyketsos-2003" target="_blank">Lyketsos 2003</a>; <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>). The other studies stated that they were randomised but did not describe the methods used for sequence generation or allocation concealment so we judged the risk of bias to be unclear. </p> <p>All 10 studies said they were double‐blind but only two reported checking on this. The nature of the placebos was not stated in two studies (<a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a>; <a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a>). In seven studies (<a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a>; <a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>; <a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>; <a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>; <a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a>; <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>; <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>), drug and placebo were described as "identical" in appearance, and in one study it was described as "matched" (<a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a>). With the exception of two studies that explicitly checked whether examiners were able to guess allocation status (<a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>; <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>), there was insufficient information to permit judgement about the integrity of blinding, therefore the risk of bias due to performance or detection bias (or both) was rated as unclear in these studies. Study clinicians correctly guessed allocation status above chance levels in the active treatment group in one study (<a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>), therefore we judged this risk of performance bias as high. </p> <p>Four studies provided intention‐to‐treat data (<a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a>; <a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>; DIADS‐2: <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a> and <a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a>; <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>), three studies only reported completers' data (<a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a>; <a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>; <a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a>), and two studies reported both types of data (<a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>; <a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a>). We combined these data in the analyses and carried out sensitivity analyses where we considered this to be appropriate. The attrition rate was very high and unbalanced between groups in three studies (<a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>; <a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a>; <a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a>), therefore we rated the attrition bias as high in these studies. In <a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a>, only 57% of patients were receiving treatment by week 24, therefore we rated the risk of attrition bias as high. </p> <p>We considered three studies to be at high risk of selective reporting bias (<a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a>; <a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a>; <a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a>). In <a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a>, both ITT and per protocol analyses were performed but only the latter was reported. The paper also mentioned response and remission analyses in the methods section, but did not report these. The other two studies reported incomplete data for the depression rating scale scores (<a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a>; <a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a>). </p> <p>Most included studies did not publish enough information for us to assess risk of bias related to funding; we considered one study to have low risk of bias (<a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>), one study to have high risk of bias (<a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a>), and the rest to have unclear risk of bias. </p> </section> <section id="CD003944-sec-0063"> <h3 class="title" id="CD003944-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD003944-tbl-0001"><b>Summary of findings for the main comparison</b> Antidepressant treatment compared with placebo for depression in dementia</a> </p> <p>See antidepressant versus placebo comparisons in <a href="./references#CD003944-sec-0083" title="">Data and analyses</a>, and <a href="./full#CD003944-tbl-0001">summary of findings Table for the main comparison</a>.<br/> <br/> We included 10 included studies with a total of 1592 participants. Two studies published results for trial completers but did not include the numbers in each treatment group who had completed (<a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1503291142077609500455715305071%26format=REVMAN#STD-Roth-1996" target="_blank">Roth 1996</a>). Therefore we were only able to use adverse events data from both of these studies. One study had a cross‐over design and we used data from the first treatment period only (<a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>). Only one study used the Montgomery‐Asberg Depression Rating Scale (MADRS) (<a href="https://archie.cochrane.org/sections/documents/view?version=z1503291142077609500455715305071%26format=REVMAN#STD-de-Vasconcelos-2007" target="_blank">de Vasconcelos 2007</a>). One study reported outcomes using both the Cornell Scale for Depression in Dementia (CSDD) and the Hamilton Depression Rating Scale (HAM‐D) (<a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>); when pooling data from all studies, we used the CSDD data from this study. </p> <p>We pooled data separately for outcomes reported at 6 to 13 weeks and 24 to 39 weeks (6 to 9 months). Two studies contributed data to both time point analyses (DIADS‐2: <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>; <a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a>, 12 and 24 weeks; <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>, 13 and 39 weeks). </p> <section id="CD003944-sec-0064"> <h4 class="title">Treatment efficacy</h4> <p>The analyses concerning efficacy included eight studies (<a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a>; <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>; <a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a>; <a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>; <a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>; <a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>; <a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a>; <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>), with a total of 614 subjects. </p> <section id="CD003944-sec-0065"> <h5 class="title">Depression (measured by rating scales)</h5> <p>We found that there was little or no effect of antidepressant treatment on depression measured with symptom scales after 6 to 13 weeks of treatment, compared to placebo (standardised mean difference (SMD) ‐0.10, 95% confidence interval (CI) ‐0.26 to 0.06; 614 participants; 8 studies; I<sup>2</sup> = 7%; <a href="./references#CD003944-fig-0009" title="">Analysis 1.1</a>; <a href="#CD003944-fig-0004">Figure 4</a>). Although this analysis included treatment with different types of antidepressants, heterogeneity was low and we considered the evidence to be of high quality. Two of the studies included in this meta‐analysis only reported completers' data (<a href="https://archie.cochrane.org/sections/documents/view?version=z1503291142077609500455715305071%26format=REVMAN#STD-Reifler-1989" target="_blank">Reifler 1989</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1503291142077609500455715305071%26format=REVMAN#STD-Petracca-1996" target="_blank">Petracca 1996</a>), therefore we carried out a sensitivity analysis excluding these studies. The result, now based entirely on intention‐to‐treat data, was unchanged and indicated little or no difference between antidepressant and placebo treatment (SMD ‐0.10, 95% CI ‐0.27 to 0.07, P = 0.24). It is of note that the two studies excluded in the sensitivity analysis (<a href="https://archie.cochrane.org/sections/documents/view?version=z1503291142077609500455715305071%26format=REVMAN#STD-Reifler-1989" target="_blank">Reifler 1989</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1503291142077609500455715305071%26format=REVMAN#STD-Petracca-1996" target="_blank">Petracca 1996</a>), investigated the effect of tricyclic antidepressants (TCAs) (drugs not commonly used in this population). </p> <div class="figure" id="CD003944-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.1 Depression endpoint mean scores at 6‐13 weeks." data-id="CD003944-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.1 Depression endpoint mean scores at 6‐13 weeks. </p> </div> </div> </div> <p>Two studies assessed outcomes after a longer treatment period: after 24 weeks, DIADS‐2 (<a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a>), and after 39 weeks (<a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>). Both measured depressive symptoms using the CSDD. We found that there was probably little or no effect of this more prolonged treatment on depressive symptoms (mean difference (MD) 0.59 point, 95% CI ‐1.12 to 2.3, 357 participants; <a href="./references#CD003944-fig-0010" title="">Analysis 1.2</a>). Heterogeneity was low (I<sup>2</sup> = 0%), but we considered this moderate‐quality evidence due to methodological limitations, as both studies had a high attrition rate and one study (DIADS‐2) also had a high risk of bias related to blinding. </p> <p>We looked separately at results from the studies which assessed depressive symptoms after 12 or 13 weeks using the CSDD (<a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>; the DIADS‐2 study in <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>; and <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>). An analysis of the findings from these three studies indicated little or no benefit from treatment with an antidepressant (MD ‐0.10 point, 95% CI ‐0.99 to 0.78; 433 participants; 3 studies; <a href="./references#CD003944-fig-0010" title="">Analysis 1.2</a>). </p> <p>In a pooled analysis of the four studies which used the Hamilton Depression Rating Scale (<a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a>; <a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>; <a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>; <a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>), there was little or no difference between placebo and antidepressant after 6 to 12 weeks of treatment (MD ‐0.85, 95% CI ‐2.65 to 0.95; participants = 134; studies = 4; I<sup>2</sup> = 24%; <a href="./references#CD003944-fig-0011" title="">Analysis 1.3</a>). </p> <p>The only study using the Montgomery‐Asberg Depression Rating Scale, <a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a>, reported no significant difference in mean score changes. </p> <p>A subgroup analysis of the five studies using a selective serotonin reuptake inhibitor (SSRI) showed little or no difference between the antidepressant and placebo groups (SMD ‐0.13, 95% CI ‐0.33 to 0.07; 400 participants; 5 studies; I<sup>2</sup> = 42%; see 1.1.1 in <a href="./references#CD003944-fig-0009" title="">Analysis 1.1</a>). There was moderate heterogeneity in the data, but nevertheless, we considered this overall to be high‐quality evidence. </p> </section> <section id="CD003944-sec-0066"> <h5 class="title">Depression (measured by rates of response or remission)</h5> <p>We also sought to examine rates of response and remission from depression. "Response" was defined as "partial response" by best clinical judgment rated by two psychiatrists (<a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>), 50% or more reduction in HAM‐D scores (<a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>), or a modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (mADCS‐CGI) rating of 2 or less (<a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a>). Data on response to treatment after 6 to 12 weeks came from two studies using an SSRI (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=047299091011000106%26versionPK1=z1803161810541397234937304984673%26versionPK2=z1803252140059408834403023633668#STD-Petracca-2001" target="_blank">Petracca 2001</a>; <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=047299091011000106%26versionPK1=z1803161810541397234937304984673%26versionPK2=z1803252140059408834403023633668#STD-Lyketsos-2003" target="_blank">Lyketsos 2003</a>). There may be a higher response rate among participants on antidepressants than on placebo (odds ratio (OR) 2.42, 95% CI 0.97 to 6.09; 85 participants; 2 studies; I<sup>2</sup> = 0%; <a href="./references#CD003944-fig-0012" title="">Analysis 1.4</a>.1; <a href="#CD003944-fig-0005">Figure 5</a>), but there is a lot of uncertainty about this result, which is also consistent with little or no effect. We considered this evidence to be low‐quality, due to indirectness (the definitions of “response” were different in the studies and some could be considered surrogate measures, e.g. “best clinical judgement”) and imprecision (comparison was underpowered due to low numbers of participants). A third study, <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=047299091011000106%26versionPK1=z1803161810541397234937304984673%26versionPK2=z1803252140059408834403023633668#STD-de-Vasconcelos-2007" target="_blank">de Vasconcelos 2007</a>, used 50% or more reduction in MADRS scores as a definition of remission as opposed to response, but to be consistent with other studies we also included their data in our meta‐analysis of response rates. When we added this third study (<a href="./references#CD003944-fig-0012" title="">Analysis 1.4</a>), the result remained imprecise with uncertainty about the direction and size of the effect (OR 1.71, 95% CI 0.80 to 3.67; 116 participants; 3 studies; I<sup>2</sup> = 13%). Only one study (DIADS‐2: Weintraub 2010) provided longer‐term data on response. The result was imprecise so the effect of antidepressants after 24 weeks was uncertain (OR 1.45, 95% CI 0.72 to 2.92; 131 participants; 1 study; I<sup>2</sup> = 0%). </p> <div class="figure" id="CD003944-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.4 Number of responders (ITT) at 6‐12 weeks." data-id="CD003944-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.4 Number of responders (ITT) at 6‐12 weeks. </p> </div> </div> </div> <p>"Remission" was defined by the authors of the studies as a HAM‐D score of seven or lower (<a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>), a HAM‐D score of seven or lower and Clinical Global Impression rating of one or two (<a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>), "full response" rated by two psychiatrists' best clinical judgment (<a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>), or a mADCS‐CGI rating of two or lower and a CSDD score of six or lower (DIADS‐2: <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>, Weintraub 2010). Although with the exception of the smallest study (<a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>), there was no significant difference in remission rates between the antidepressant and placebo treated groups reported in individual studies, a meta‐analysis indicated that at 6 to 12 weeks remission rates favoured antidepressant over placebo (OR 2.57, 95% CI 1.44 to 4.59; 240 participants; 4 studies; I<sup>2</sup> = 0%; <a href="./references#CD003944-fig-0014" title="">Analysis 1.6</a>; <a href="#CD003944-fig-0006">Figure 6</a>). We regarded this as moderate‐quality evidence due to indirectness (i.e. definitions of “remission” were different in the studies and some could be considered surrogate measures, e.g. “best clinical judgement”). A subgroup analysis of the SSRI studies indicated that remission rates were higher in the antidepressant group than in the placebo group (OR 2.22, 95% CI 1.20 to 4.12; 216 participants; 3 studies; I<sup>2</sup> = 0%; <a href="./references#CD003944-fig-0014" title="">Analysis 1.6</a>), based on evidence graded as low‐quality due to indirectness and imprecision (comparison was underpowered due to low number of participants). Again, only one study (DIADS‐2: Weintraub 2010) provided longer term data and the result was imprecise so the effect of antidepressants on remission after 24 weeks is uncertain (OR 1.75, 95% CI 0.80 to 3.82; 131 participants; 1 study; <a href="./references#CD003944-fig-0015" title="">Analysis 1.7</a>). </p> <div class="figure" id="CD003944-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.6 Number of patients with remission (ITT) at 6‐12 weeks." data-id="CD003944-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.6 Number of patients with remission (ITT) at 6‐12 weeks. </p> </div> </div> </div> </section> <section id="CD003944-sec-0067"> <h5 class="title">Cognitive function</h5> <p>Meta‐analyses of cognitive function measured with the Mini Mental State Examination (MMSE) showed that there was probably little or no difference between antidepressant or placebo at weeks 6 to 12, whether the outcome was endpoint mean scores (MD 0.33 point, 95% CI ‐1.31 to 1.96; 194 participants; 5 studies; I<sup>2</sup> = 0%; <a href="./references#CD003944-fig-0016" title="">Analysis 1.8</a>) or change in mean scores (MD 0.19 point, 95% CI ‐0.81 to 1.19; 5 studies; <a href="./references#CD003944-fig-0017" title="">Analysis 1.9</a>). This was also true in sensitivity analyses looking at endpoint intention‐to‐treat (ITT) data (<a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>; <a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>: MD ‐0.76 point, 95% CI ‐3.78 to 2.27, P = 0.62) or completers‐only data (<a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a>; <a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>; <a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>: MD ‐0.34 point, 95% CI ‐3.06 to 2.39; P = 0.81; analysis not presented). We regarded this as moderate‐quality evidence due to imprecision (relatively few participants and wide confidence intervals). There was also no evidence of a difference between groups at six to nine months for endpoint mean scores (MD 1.00 point, 95% CI ‐1.14 to 3.14; 131 participants; 1 study; see Analyis 1.7.2) or change in mean scores (MD ‐0.38 point, 95% CI ‐1.90 to 1.13; 2 studies; <a href="./references#CD003944-fig-0017" title="">Analysis 1.9</a>) on the MMSE. </p> </section> <section id="CD003944-sec-0068"> <h5 class="title">Activities of daily living</h5> <p>Five studies measured performance of activities of daily living (ADLs) using different scales (<a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a>; <a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>; <a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>; <a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>; <a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a>). We were able to pool data from four studies to estimate a standardised mean difference between groups; we had to exclude the data from <a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>, because they were available only as change‐from‐baseline while the other studies reported endpoint scores. There was little or no difference between antidepressants and placebo as regards ADLs at weeks 6 to 13 (SMD ‐0.05, 95% CI ‐0.36 to 0.25; 173 participants; 4 studies; I<sup>2</sup> = 20%; <a href="./references#CD003944-fig-0018" title="">Analysis 1.10</a>, <a href="#CD003944-fig-0007">Figure 7</a>). We considered this to be high‐quality evidence. The only study that reported data at six to nine months (Weintraub 2010) did not indicate any difference between groups either. </p> <div class="figure" id="CD003944-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.10 Activities of daily living, endpoint values at 6‐13 weeks." data-id="CD003944-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.10 Activities of daily living, endpoint values at 6‐13 weeks. </p> </div> </div> </div> </section> <section id="CD003944-sec-0069"> <h5 class="title">Quality of life</h5> <p>We could not pool the results on quality‐of‐life outcomes from two studies (Weintraub 2010; <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>), as they reported data in very different formats. Neither study reported any significant difference by treatment group. </p> </section> </section> <section id="CD003944-sec-0070"> <h4 class="title">Dropouts and adverse effects</h4> <section id="CD003944-sec-0071"> <h5 class="title">Tolerability (measured as withdrawal from trial)</h5> <p>Data from nine studies indicated that participants on antidepressant treatment were probably more likely to drop out of the study over 6 to 13 weeks (OR 1.51, 95% CI 1.07 to 2.14; 836 participants; 9 studies; I<sup>2</sup> = 0%; <a href="./references#CD003944-fig-0020" title="">Analysis 1.12</a>; <a href="#CD003944-fig-0008">Figure 8</a>). We graded this evidence as moderate‐quality due to imprecision. Subgroup analyses looking at SSRIs, venlafaxine, mirtazapine, and older antidepressants separately found that placebo was consistently favoured, but the results for the individual antidepressants were associated with more uncertainty and in each case were also consistent with little or no difference between groups. There was no clear evidence of a difference between groups after six to nine months (OR 1.25, 95% CI 0.83 to 1.88; 457 participants; 2 studies; <a href="./references#CD003944-fig-0021" title="">Analysis 1.13</a>), on the basis of evidence rated as moderate‐quality due to imprecision. </p> <div class="figure" id="CD003944-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.12 Tolerability: Number of dropouts at 6‐13 weeks." data-id="CD003944-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.12 Tolerability: Number of dropouts at 6‐13 weeks. </p> </div> </div> </div> </section> <section id="CD003944-sec-0072"> <h5 class="title">Safety (measured by the incidence of adverse effects)</h5> <p>Participants taking an antidepressant were probably more likely to experience at least one adverse event at 6 to 13 weeks (Peto OR 1.55, 95% CI 1.21 to 1.98; 1073 participants; 3 studies; I<sup>2</sup> = 26%; <a href="./references#CD003944-fig-0022" title="">Analysis 1.14</a>), although we considered the evidence to be moderate‐quality due to publication bias. This effect was more pronounced with SSRIs and older antidepressants, whilst the Peto OR in the mirtazapine data was not significant. There were statistically significant differences in favour of placebo for numbers of participants experiencing dry mouth (Peto OR 1.80, 95% CI 1.23 to 2.63; 1044 participants; 5 studies; I<sup>2</sup> = 55%; <a href="./references#CD003944-fig-0023" title="">Analysis 1.15</a>) and dizziness (Peto OR 2.00, 95% CI 1.34 to 2.98; 1044 participants; 5 studies; I<sup>2</sup> = 29%; <a href="./references#CD003944-fig-0026" title="">Analysis 1.18</a>). We rated the evidence for both these outcomes as high‐quality. Subgroup analyses revealed similar patterns with SSRIs and older antidepressants for both outcomes. There were no statistically significant differences found for fatigue (quality of the evidence rated as low due to selective reporting and imprecision; <a href="./references#CD003944-fig-0024" title="">Analysis 1.16</a>) or constipation (quality of evidence rated as moderate due to imprecision; <a href="./references#CD003944-fig-0025" title="">Analysis 1.17</a>). </p> <p>Data on serious adverse events (SAEs) were reported in a number of the included studies but unfortunately in different formats, therefore they could not be pooled. <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>, which looked at data at 13 weeks, reported 15 SAEs in the placebo group, 12 in the sertraline group, and 14 in the mirtazapine group; out of these, 3, 8, and 10 were severe, respectively, suggesting that although the overall number of SAEs did not differ between groups, more of these events were severe in those participants on antidepressants compared with placebo. Over 24 weeks in the DIADS‐2 study (Weintraub 2010), SAEs occurred in 27.3% of participants on sertraline compared with 12.7% of those on placebo. Petracca and colleagues reported serious side effects in one participant who was in the group treated with an antidepressant (<a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>); and in <a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a>, 27.4% of the adverse events were rated as severe in the placebo group compared with 29% in the moclobemide group (however it should be noted that their "safety" population included both participants with dementia with depressive symptoms and those with depression with cognitive decline). Overall, it seems that SAEs occurred more often in those participants given antidepressants compared to those on placebo. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003944-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003944-sec-0073">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003944-sec-0133">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003944-sec-0073"></div> <section id="CD003944-sec-0074"> <h3 class="title" id="CD003944-sec-0074">Summary of main results</h3> <p>Meta‐analyses of outcome measures relating to antidepressant treatment efficacy revealed little or no effect of antidepressants on depression rating scale mean scores at 6 to 12 weeks (high‐quality evidence) or at 6 to 9 months (moderate‐quality evidence). There was also no clear evidence of an effect of treatment on the number of responders (low‐quality evidence). We found moderate‐quality evidence favouring antidepressants in the comparison of remission rates at 6 to 12 weeks, but the result at 24 weeks was imprecise and we could not be sure that the difference was maintained. </p> <p>Subgroup analyses looking at selective serotonin reuptake inhibitors (SSRIs), venlafaxine, mirtazapine, and tricyclic antidepressants (TCAs) separately did not indicate differences between these subgroups. A sensitivity analysis looking at studies which measured depression with the Cornell Scale for Depression in Dementia (CSDD), which is designed specifically to assess depression in dementia, found little or no effect of antidepressants when compared to placebo. </p> <p>There was little or no difference in measures of cognitive function (Mini Mental State Examination (MMSE) scores) or activities of daily living between antidepressant and placebo groups (moderate‐ and high‐quality evidence, respectively). </p> <p>Participants taking antidepressants were probably more likely to drop out of treatment and more likely to experience at least one adverse event over 6 to 12 weeks. Patients on antidepressant were significantly more likely to experience dry mouth or dizziness, but not fatigue or constipation. </p> </section> <section id="CD003944-sec-0075"> <h3 class="title" id="CD003944-sec-0075">Overall completeness and applicability of evidence</h3> <p>The process of combining data from differing studies is problematic. The assumption is that the study samples are drawn from similar populations but the validity of this assumption is difficult to assess. The adherence to the inclusion criteria for studies ensures some homogeneity in that all participants included in the review meet recognised criteria for both depression and dementia. </p> <p>As discussed earlier, the relationship between depression and dementia is complex, and depression is more difficult to diagnose in patients with dementia. DSM criteria for depression include anhedonia and poor concentration, which are both symptoms of dementia. Some studies attempted to take this potentially confounding factor into account when making the diagnosis of depression (<a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>; <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>; <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>). A further concern is that only one of the depression rating scales used in the included studies was developed for the specific purpose of measuring depression in dementia (CSDD). Other instruments used in the included studies were developed in younger subjects and may underestimate depression in older patients because of the atypical nature of depression in older people (e.g. the Hamilton Depression Scale, HAM‐D). Even where scales are designed specifically for the older population, they may not be reliable in the specific scenario of depression in dementia (e.g. the Geriatric Depression Scale) (<a href="./references#CD003944-bbs2-0065" title="BurnsA , LawlorB , CraigS . Rating Scales in Old Age Psychiatry. British Journal of Psychiatry2002;180:161‐7. ">Burns 2002</a>). Assessing response to treatment and remission is also fraught with difficulties in these patients. </p> <p>Depression and dementia are both highly heterogeneous conditions. Patients with mild dementia who are unhappy at the threat to future independence which their diagnosis represents, may be different from those with a MMSE of 15, apathy, anhedonia, low mood and intermittent anxiety. Theoretically, this difference has the potential to obscure potentially useful benefits of antidepressants in patient subgroups. There was no important heterogeneity in our meta‐analysis. However, this might be because all studies examined patients with a wide range of MMSE scores. It should therefore be regarded as absence of evidence rather than evidence of absence. </p> <p>We only included studies using formal criteria for depression to improve the reliability and clinical applicability of our findings, thereby including the more severe end of the depressive spectrum which is more likely to respond to antidepressant treatment. </p> <p>It cannot be excluded that adjuvants (e.g. lithium or antipsychotics) or combination treatments (not studied in this review) could show a significant effect in the treatment of patients with depression in dementia. </p> <p>It is of note that activities of daily living and especially dementia‐specific quality‐of‐life measures have only been used in the more recent studies. </p> </section> <section id="CD003944-sec-0076"> <h3 class="title" id="CD003944-sec-0076">Quality of the evidence</h3> <p>As presented in the 'Risk of bias' and 'Summary of findings' tables, the quality of the evidence for most outcomes was of moderate‐ or low‐quality principally due to risk of bias and imprecision. </p> <p>The analysis of adverse event data in these studies was particularly difficult due to a number of factors. There was considerable heterogeneity in the reporting of adverse events across the studies in terms of comprehensiveness, mode of ascertainment, and format. Some studies reported all or nearly all side effects and adverse events, some grouped these into systems (e.g. respiratory system, gastrointestinal system, etc.), some only reported serious adverse events, and some a mixture of these. Ideally, figures for all categories should be reported in order that results from different studies (often using different medications) can be meta‐analysed. The studies also differed in terms of whether they relied on spontaneous reporting or various types of questioning. Some reports included the total number of adverse events, others only published the number (or percentages) of participants reporting side effects, or those who withdrew from the study due to adverse events. Tolerability ratings (very good, good, etc.) presented by the investigator appear a subjective measure. Only one study made explicit reference to accepted guidelines in how the authors defined serious adverse events (SAEs) (<a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>). They used the Food and Drug Administration definition, i.e. any adverse drug experience occurring at any dose that resulted in any of the following: death, a life‐threatening adverse experience, inpatient hospitalisation or prolongation of existing hospitalisation, or persistent or significant disability/incapacity. Following a set of consistent guidelines on reporting would significantly enhance the reliability of the evidence base. </p> </section> <section id="CD003944-sec-0077"> <h3 class="title" id="CD003944-sec-0077">Potential biases in the review process</h3> <p>It is unfortunate that the results of two of the ten studies (<a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a>, <a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a>) included in this update could not be included in the efficacy meta‐analysis, as they did not include the numbers in each treatment group who had completed the study. The authors of the studies were contacted and statistical elaboration requested, but for various reasons elaboration did not prove possible. This is of particular regret with regards to <a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a>, as it was a large multi‐centre study with 476 participants meeting inclusion criteria for the review and the authors reported positive results. It is a limitation of our study that in order to be able to enter the sertraline and mirtazapine arms of <a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>, we had to split the control group into two groups which remained correlated. </p> <p>We used endpoint data as opposed to change from baseline, as the latter are often not reported and calculating the standard deviation from the reported data is problematic. </p> <p>It is also possible that our study has failed to find an effect that really exists (type 2 error). We argue that this possibility is less likely, as we have minimised the amount of data manipulation and simply combined symptom scores; therefore unwitting biases are less likely to have emerged. </p> </section> <section id="CD003944-sec-0078"> <h3 class="title" id="CD003944-sec-0078">Agreements and disagreements with other studies or reviews</h3> <p>Other reviews of this subject have been published. A review by Starkstein and colleagues, <a href="./references#CD003944-bbs2-0097" title="StarksteinSE , MizrahiR . Depression in Alzheimer's disease. Expert Review of Neurotherapeutics2006;6(6):887‐95. ">Starkstein 2006</a>, drew attention to two individual studies that are also included in our analysis (<a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a>; <a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>), and reported efficacy in the treatment of depression in dementia with sertraline and moclobemide, respectively. </p> <p>A systematic review by Thompson and colleagues concluded that antidepressants were efficacious (<a href="./references#CD003944-bbs2-0099" title="ThompsonS , HerrmannN , RapoportMJ , et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Canadian Journal of Psychiatry ‐ Revue Canadienne de Psychiatrie2007;52(4):248‐55. ">Thompson 2007</a>). This review examined antidepressants in Alzheimer's disease rather than just in dementia as a whole but this difference is unlikely to have been important, as the authors included four of the same studies that we have used here (<a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a>; <a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>; <a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>; <a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>). The fifth study used by Thompson and colleagues, <a href="./references#CD003944-bbs2-0031" title="MagaiC , KennedyG , CohenCI , GombergD . A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late‐stage Alzheimer's disease. American Journal of Geriatric Psychiatry2000;8:66‐74. ">Magai 2000</a>, was excluded from our review because only 10% of the sample had diagnosed major depression and we felt the validity of the diagnosis of depression was questionable and not comparable with other studies, considering that they had to rely on proxy measures in a patient population much more severely demented than in the other studies included. Proxy measures included cut‐off scores on the Cornell Scale and the Gestalt Depression Scale (<a href="./references#CD003944-bbs2-0073" title="GreenwaldB , Kramer‐GinsbergE , KremenNJ , et al. Depression complicating dementia. Presented at American Psychiatric Association Annual Meeting, New OrleansMay 1991. ">Greenwald 1991</a>), and also analysis of facial expression. Thompson and colleagues adopted a different approach, namely to define cases as responders on the basis of a 50% reduction in their depression scores (HAM‐D or other) or as achieving remission (HAM‐D score of less than eight, or equivalent) (<a href="./references#CD003944-bbs2-0099" title="ThompsonS , HerrmannN , RapoportMJ , et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Canadian Journal of Psychiatry ‐ Revue Canadienne de Psychiatrie2007;52(4):248‐55. ">Thompson 2007</a>). However, the authors also went on to state that: "Other definitions of depression remission or response were considered if they were deemed clinically valid and (or) relevant". In contrast, we have looked at depression scores as continuous variables as well as examining response and remission. Introducing criteria for response and remission carries the possibility of introducing a bias in favour of treatment (type 1 error). In their narrative review, Farina and colleagues also concluded that antidepressants are not effective for depression (<a href="./references#CD003944-bbs2-0068" title="FarinaN , MorrellL , BanerjeeS . What is the therapeutic value of antidepressants in dementia? A narrative review. International Journal of Geriatric Psychiatry2017;32(1):32‐49. ">Farina 2017</a>). </p> <p>Another review, which included the de Vasconcelos and Rosenberg studies (both of which reported lack of efficacy) in addition to the same ones included in the Thompson review, was in accordance with our findings (<a href="./references#CD003944-bbs2-0086" title="NelsonJC , DevanandDP . A systematic review and meta‐analysis of placebo‐controlled antidepressant studies in people with depression and dementia. Journal of the American Geriatrics Society2011;59(4):577‐85. ">Nelson 2011</a>). A meta‐analysis by Sephery and colleagues, <a href="./references#CD003944-bbs2-0095" title="SepehryAA , LeePE , HsiungGYR , BeattieBL , JacovaC . Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with Comorbid depression: a meta‐analysis of depression and cognitive outcomes. Drugs and Aging2012; Vol. 29, issue 10:793‐806. ">Sepehry 2012</a>, found a lack of efficacy for antidepressants based on data from five studies. Several other recent reviews also noted the limited evidence and concluded that more studies were needed (<a href="./references#CD003944-bbs2-0083" title="ModregoPJ . Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment. [Review]. Journal of Alzheimer's Disease2010; Vol. 21, issue 4:1077‐87. ">Modrego 2010</a>; <a href="./references#CD003944-bbs2-0094" title="SaarinenJ , KivelaSL , RaihaI . [The effects of antidepressive drugs among the patients with memory disturbances—a systematic review]. Duodecim; laaketieteellinen aikakauskirja2010; Vol. 126, issue 21:2503‐9. ">Saarinen 2010</a>; <a href="./references#CD003944-bbs2-0074" title="HaightT , ChengH . Antidepressant treatment for older adults with dementia and depression: re‐visit the evidence from randomized controlled trials (RCT). Journal of the American Geriatrics Society. 2013; Vol. Conference: 2013 Annual Scientific Meeting of the American Geriatrics Society Grapevine, TX United States. Conference Start: 20130503 Conference End: 20130505.:var.pagings. ">Haight 2013</a>; <a href="./references#CD003944-bbs2-0079" title="LeongC . Antidepressants for depression in patients with dementia: A review of the literature. Consultant Pharmacist2014; Vol. 29, issue 4:254‐63. ">Leong 2014</a>; <a href="./references#CD003944-bbs2-0089" title="OrgetaV , TabetN , NilforooshanR , HowardR . Efficacy of antidepressants for depression in Alzheimer’s Disease: systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;58(3):725‐33. ">Orgeta 2017</a>). </p> <p>Our findings are also somewhat different to some other reviews regarding drug safety. The Thompson review reported dropouts from treatment due to all causes and due to adverse events, but did not examine individual symptoms. From this relatively broad approach, they found no significant differences. However, we have analysed data regarding several side effects and found that participants treated with antidepressants experienced significantly more adverse events. It should be noted that three studies that contributed to this analysis were not available to Thompson and colleagues (the Banerjee, de Vasconcelos, and DIADS‐2 studies). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003944-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003944-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003944-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003944-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.1 Depression endpoint mean scores at 6‐13 weeks." data-id="CD003944-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.1 Depression endpoint mean scores at 6‐13 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.4 Number of responders (ITT) at 6‐12 weeks." data-id="CD003944-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.4 Number of responders (ITT) at 6‐12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.6 Number of patients with remission (ITT) at 6‐12 weeks." data-id="CD003944-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.6 Number of patients with remission (ITT) at 6‐12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.10 Activities of daily living, endpoint values at 6‐13 weeks." data-id="CD003944-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.10 Activities of daily living, endpoint values at 6‐13 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.12 Tolerability: Number of dropouts at 6‐13 weeks." data-id="CD003944-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.12 Tolerability: Number of dropouts at 6‐13 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 1 Depression endpoint mean scores at 6‐13 weeks." data-id="CD003944-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 1 Depression endpoint mean scores at 6‐13 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 2 Cornell Scale for Depression in Dementia (CSDD)." data-id="CD003944-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 2 Cornell Scale for Depression in Dementia (CSDD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 3 Hamilton Depression rating Scale (HDRS)." data-id="CD003944-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 3 Hamilton Depression rating Scale (HDRS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 4 Number of responders (ITT) at 6‐12 weeks." data-id="CD003944-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 4 Number of responders (ITT) at 6‐12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 5 Number of responders (ITT) at 24 weeks." data-id="CD003944-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 5 Number of responders (ITT) at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 6 Number of patients with remission (ITT) at 6‐12 weeks." data-id="CD003944-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 6 Number of patients with remission (ITT) at 6‐12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 7 Number of patients with remission (ITT) at 24 weeks." data-id="CD003944-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 7 Number of patients with remission (ITT) at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 8 Cognitive function endpoint mean scores." data-id="CD003944-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 8 Cognitive function endpoint mean scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 9 Change in MMSE mean scores." data-id="CD003944-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 9 Change in MMSE mean scores.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 10 Activities of daily living, endpoint values at 6‐13 weeks." data-id="CD003944-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 10 Activities of daily living, endpoint values at 6‐13 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 11 Activities of daily living at 6‐9 months." data-id="CD003944-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 11 Activities of daily living at 6‐9 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-12.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 12 Tolerability: Number of dropouts at 6‐13 weeks." data-id="CD003944-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 12 Tolerability: Number of dropouts at 6‐13 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 13 Tolerability: Number of dropouts at 6‐9 months." data-id="CD003944-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 13 Tolerability: Number of dropouts at 6‐9 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 14 Safety: number experiencing at least one adverse event." data-id="CD003944-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 14 Safety: number experiencing at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 15 Safety: N experiencing at least one event of dry mouth." data-id="CD003944-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 15 Safety: N experiencing at least one event of dry mouth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 16 Safety: N experiencing at least one event of fatigue." data-id="CD003944-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 16 Safety: N experiencing at least one event of fatigue. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 17 Safety: N experiencing at least one event of constipation." data-id="CD003944-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 17 Safety: N experiencing at least one event of constipation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003944-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/urn:x-wiley:14651858:media:CD003944:CD003944-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_t/tCD003944-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antidepressant versus placebo, Outcome 18 Safety: N experiencing at least one event of dizziness." data-id="CD003944-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Antidepressant versus placebo, Outcome 18 Safety: N experiencing at least one event of dizziness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/media/CDSR/CD003944/image_n/nCD003944-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003944-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antidepressant treatment compared with placebo for depression in dementia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antidepressant treatment compared with placebo for depression in dementia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with depression and dementia </p> <p><b>Settings:</b> outpatient (except Roth 1996, which was mixed in‐ and outpatients) </p> <p><b>Intervention:</b> antidepressant treatment </p> <p><b>Comparison:</b> placebo treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antidepressant</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression endpoint mean scores at 6 to 13 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised depression ratings scale endpoint mean score in the antidepressant group was <b>0.10 points lower</b> (0.26 lower to 0.06 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>614<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of an effect of antidepressants on depression in dementia</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of responders (ITT) at 6 to 12 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>509 per 1000</b> </p> <p>(326 to 690)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.71</b> (0.80 to 3.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of an effect of antidepressants regarding response to treatment for depression in dementia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with remission (ITT) at 6 to 12 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000‏</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>415 per 1000</b> </p> <p>(285 to 559)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.57</b> [1.44, 4.59] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of a positive effect of antidepressants on remission of depression in dementia</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function endpoint mean scores at 6 to 12 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The MMSE endpoint mean score in the antidepressant group was <b>0.33 points higher</b> [1.31 lower to 1.96 higher] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(194)<br/> (5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of an effect of antidepressants on cognitive function in patients with depression and dementia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living, endpoint values at 6 to 13 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean difference in ADL endpoint mean scores in the antidepressant group was <b>0.05 points lower</b> [0.36 lower to 0.25 higher] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of an effect of antidepressants on ADLs in patients with depression and dementia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of dropouts at 6 to 13 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>248 per 1000</b> </p> <p>(189 to 318)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.51</b> </p> <p>(1.07 to 2.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>836<br/> (9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of a negative effect of antidepressants on staying in treatment in patients with depression in dementia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients experiencing at least one adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>384 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b> </p> <p>(430 to 553)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.55</b> </p> <p>(1.21 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1073<br/> (5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of a negative effect of antidepressants related to side effects in patients with depression and dementia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Risk Ratio; <b>ITT:</b> intention‐to‐treat; <b>MMSE:</b> Mini–Mental State Examination </p> <p>A SMD of 0.2 is often considered to represent a small effect size, 0.5 a moderate effect size and 0.8 a large effect size. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different </p> <p><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect </p> <p><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The quality of the evidence was downgraded due to indirectness (the definitions of “response” were different in the studies and some could be considered surrogate measures, e.g. “best clinical judgement”) and imprecision (comparison was underpowered due to low number of total number of participants). </p> <p><sup>2</sup>The quality of the evidence was downgraded due to indirectness (the definitions of “remission” were different in the studies and some could be considered surrogate measures, e.g. “best clinical judgement”). </p> <p><sup>3</sup>The quality of the evidence was downgraded due to imprecision (relatively low number of participants and wide confidence intervals). </p> <p><sup>4</sup> The quality of the evidence was downgraded due to imprecision (the analysis is underpowered; also, the 95% CI around the pooled or best estimate of effect include both little effect and appreciable harm). </p> <p><sup>5</sup>The quality of evidence was downgraded due to selective reporting. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antidepressant treatment compared with placebo for depression in dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003944-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome measures</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Abbreviation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Brief description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Used in</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><i>Depression rating scales</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hamilton Depression Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HAMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0075" title="Hamilton , M . A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry1960;23:56‐62. ">Hamilton 1960</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>depressive symptom levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinician‐rated, multiple choice rating scale of depressive symptom severity designed to be sensitive to change with treatment in the general adult population. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a>, <a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>, <a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a>, <a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cornell Scale for Depression in Dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0058" title="AlexopoulosGS , AbramsRC , YoungRC , ShamoianCA . Cornell Scale for Depression in Dementia. Biological Psychiatry1988;23(3):271‐84. ">Alexopoulos 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>depressive symptom levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For the diagnosis of depression in patients with a dementia syndrome administered by a clinician. It takes 20 minutes with the carer and 10 minutes with the patient. The scale has 19 items, rated on a 3 point scale: absent, mild or intermittent and severe, based on the week prior to the interview. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a>, <a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a><a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a>, </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Montgomery Asberg Depression Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MADRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0084" title="MontgomerySA , ÅsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382‐89. ">Montgomery 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>depressive symptom levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A 10‐item clinician‐rated diagnostic questionnaire to measure the severity of depressive symptomatology in mood disorders. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geriatric Depression Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0105" title="YesavageJA , BrinkTL , RoseTL , et al. Development and validation of a geriatric depression screening scale: a preliminary report. Journal of Psychiatric Research1982;17(1):37‐49. ">Yesavage 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>depressive symptom levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A 30‐item, self‐report assessment used to identify depression in the elderly. The simple response format (yes/no questions) makes it more suitable for use in those with cognitive impairment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><i>Cognitive measure</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mini‐mental State Examination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0069" title='FolsteinMF , FolsteinSE , McHughPR . "Mini‐mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12(3):189‐98. '>Folstein 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>level of cognitive functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A 30‐point clinician‐administered cognitive test for cognitive impairment, assessing orientation, concentration, memory, language, and visuo‐spatial function. Higher scores indicate better functioning. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All included studies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><i>Activities of daily living</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Psychogeriatric dependency rating scales ‐ ADL subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PGDRS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0103" title="WilkinsonIM , Graham‐White , J . Psychogeriatric dependency rating scales (PGDRS): a method of assessment for use by nurses. British Journal of Psychiatry1980;137:558‐65. ">Wilkinson 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>need for assistance with functional abilities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physical capacity consists of 7 sub‐categories. Higher scores indicate more disability.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADCS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0070" title="GalaskoD , BennettD , SanoM , et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Disease and Associated Disorders1997;11(suppl 2):33S‐39S. ">Galasko 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>functional ability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Informant‐based, last 4 weeks. Higher score indicates better performance.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Functional Independence Measure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FIM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0072" title="GrangerCV , HamiltonBB , KaytonR . Functional Independence Measure. Guide for use of the uniform data set for medical rehabilitation. Buffalo, NY: Uniform Data System for Medical Rehabilitation, 1986. ">Granger 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>need for assistance with functional abilities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 items on self‐care, sphincter control, mobility, locomotion, communication, social cognition. Higher scores indicate more disability. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a>, <a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older American Resources and Services</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OARS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0091" title="PfeifferE . Multidimensional functional assessment: The OARS methodology. Durham, North Carolina: Center for the Study of Aging and Human Development1975. ">Pfeiffer 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>functional ability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An 14‐item assessment for physical function, including bathing, dressing, grooming, and continence, relying on self report. Higher scores indicate better functioning. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seoul‐Instrumental Activities of Daily Living</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0078" title="KuHM , KimJH , KwonEJ , KimSH , LeeHS , KoHJ , et al. A Study on the Reliability and Validity of Seoul‐Instrumental Activities of Daily Living(S‐IADL). Journal of Korean Neuropsychiatric Association2004;43(2):189‐99. ">Ku 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>instrumental everyday activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A 15‐item instrument to assess complex functions of daily living, with a total score from 0 to 45. Higher scores reflect worse function. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome measures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003944-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics and diagnostic criteria ‐ included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>dementia criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>depression criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>number of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean depression rating scale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0001" title="AnH , ChoiB , ParkK‐W , KimD‐H , YangD‐W , HongCH , et al. The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects. Journal of Alzheimer's disease2017;2:727‐35. ">An 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NINCDS‐ADRDA for AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>three or more from Olin's criteria for depression in AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 mg/day of escitalopram, increased 5 mg/day every two weeks, up to a maximum dosage of 15 mg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.2 (6.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSDD: 11.39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0002" title="BanerjeeS , HellierJ , DeweyM , RomeoR , BallardC , BaldwinR , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD Trial ‐ a multicentre randomised double‐blind, placebo‐controlled trial of the clinical effectiveness of sertraline and mirtazapine. Lancet2011;378:403‐11. BanerjeeS , HellierJ , RomeoR , DeweyM , KnappM , BallardC , et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial ‐ a multicentre, randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technology AssessmentMarch 2013; Vol. 17, issue 7. RomeoR , KnappM , HellierJ , DeweyM , BallardC , BaldwinR , et al. Cost‐effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry2013;202:121‐8. ">Banerjee 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NINCDS‐ADRDA for probable or possible AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>depression ≥ 4 weeks's duration potentially needing antidepressants; CSDD ≥ 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sertraline 70 mg/d (target dose: 150 mg/d), mirtazapine 24 mg/d (target dose: 45 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSDD: 12.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0003" title="deVasconcelos CunhaUG , Lopes RochaF , Avila de MeloR , et al. A placebo‐controlled double‐blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia &amp; Geriatric Cognitive Disorders2007;24(1):36‐41. ">de Vasconcelos 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐IV for dementia (AD, VD, and mixed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐IV major depressive disorder and CSDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>venlafaxine (37.5‐131.25 mg/d, mean = 75 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.6 (6.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(range: 10‐24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MADRS: 24.5 (7.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0004" title="FuchsA , HehnkeCH , ErhartC , SchnellC , PramshohlerB , DanningerB , et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry1993;26:37‐41. ">Fuchs 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III‐R for PDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III‐R 290.21(mildly depressed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>maprotiline (25 mg titrated to 75 mg/d, mean max. dose 59 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (48‐96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.4 (0‐30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS (median): 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0005" title="LyketsosCG , DelCampoL , SteinbergM , MilesQ , SteeleCD , MunroC , et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry2003;60(7):737‐46. LyketsosCG , SheppardJME , SteeleCD , KopunkeC , BakerAS , BrandtJ , et al. A randomized, placebo‐controlled, double‐blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Conference Proceedings World Alzheimer Congress; 9‐13 July, 2000; Washington DC. 2000. MayerLS , BayRC , PolitisA , et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry2006;21(10):930‐6. MunroC , LyketsosC . Cognitive response to sertraline treatment for depression in Alzheimer's disease: a possible sex effect. Research and Practice in Alzheimer's Disease2006;11:361‐5. MunroCA , BrandtJ , SheppardJ‐ME , SteeleCD , SamusQM , SteinbergM , et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). American Journal of Geriatric Psychiatry2004; Vol. 12, issue 5:491‐8. MunroCA , BrandtJ , SheppardJM , SamusQM , SteinbergM , RabinsPV , et al. Secondary outcomes from the depression in Alzheimer's disease Study (DIADS). American Journal of Geriatric Psychiatry2004;12(5):491‐8. SteinbergM , MunroCA , SamusQ , et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry2004;19:144‐50. ">Lyketsos 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NINCDS‐ADRDA for probable AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐VI for major depressive episode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sertraline (25 mg titrated to 150 mg/d, mean peak dose 113 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ham‐D: 22.75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0006" title="PetraccaG , TesonA , ChemerinskiE , LeguardaR , StarksteinSE . A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences1996;8(3):270‐5. ">Petracca 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NINCDS‐ADRDA for probable AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III‐R for dysthymia or major depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks + 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clomipramine (25 mg titrated to 100 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 (7.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.5 (6.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ham‐D:17.5 (6.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0007" title="PetraccaGM , ChemerinskiE , StarksteinSE . A double‐blind, placebo‐controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics2001;13(2):233‐240. ">Petracca 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NINCDS‐ADRDA for probable AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐IV criteria for either major or minor depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluoxetine (10 mg titrated to 40 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ham‐D: 16.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0008" title="ReiflerBV , TeriL , RaskindM , VeithR , BarnesR , WhiteE , et al. Double‐blind trial of imipramine in Alzheimer's disease patients with and without depression. American Journal of Psychiatry1989;146(1):45‐9. TeriL , ReiflerBV , VeithRC , BarnesR , WhiteE , McLeanP , et al. Imipramine in the treatment of depressed Alzheimer's disease: impact on cognition. Journals of Gerontology: Psychological Sciences1991;46(6):372‐7. ">Reifler 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III for PDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III (major depressive disorder)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>imipramine (mean dose 83 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.5 (5.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ham‐D: 18.9 (3.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐IV for AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criteria for depression of AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sertraline 50 mg/d increased to 100 mg/d, mean = 93.1 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.3 (8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 (4.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSDD (median): 13 (1st and 3rd quartile: 9, 18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0010" title="RothM , MountjoyCQ , Amrein R and the International Collaborative Study Group. Moclobemide in elderly patients with cognitive decline and depression: an international double‐blind, placebo‐controlled trial. British Journal of Psychiatry1996;168(2):149‐57. ">Roth 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III for dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐III for major depressive episode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moclobemide (400 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.4 (8.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.2 (4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.5 (5.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003944-bbs2-0011" title="LyketsosCG . Depression in Alzheimer's disease (DIADS 2). ClinicalTrials.gov2004. [Study ID Numbers: 1U0166136; ClinicalTrials.gov Identifier: NCT00086138] MartinBK , FrangakisCE , RosenbergPB , et al. Design of Depression in Alzheimer's Disease Study‐2. American Journal of Geriatric Psychiatry2006;14(11):920‐30. MunroCA , LongmireCF , DryeLT , MartinBK , FrangakisCE , MeinertCL , et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. American Journal of Geriatric Psychiatry2012; Vol. 20, issue 12:1036‐44. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. WeintraubD , RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , et al. Sertraline for the treatment of depression in alzheimer disease: Week‐24 outcomes. American Journal of Geriatric Psychiatry2010;18(4):332‐40. ">Weintraub 2010</a> </p> <p>(extension of <a href="./references#CD003944-bbs2-0009" title="DryeLT , MartinBK , FrangakisCE , MeinertCL , MintzerJE , MunroCA , et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?. International Journal of Geriatric Psychiatry2011;26(6):573‐83. Flynn LongmireCV , DryeLT , FrangakisCE , MartinBK , MeinertCL , MintzerJE , et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression In Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry2014; Vol. 22, issue 1:14‐24. RosenbergPB , DryeLT , MartinBK , FrangakisC , MintzerJE , WeintraubD , et al. Sertraline for the treatment of depression in alzheimer disease. American Journal of Geriatric Psychiatry2010;18(2):136‐45. ">Rosenberg 2010</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSM‐IV for AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criteria for depression of AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>randomised treatment with sertraline for at least partial responders after week 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.3 (8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 (4.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSDD (median): 13 (1st and 3rd quartile: 9, 18)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics and diagnostic criteria ‐ included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/full#CD003944-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003944-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antidepressant versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Depression endpoint mean scores at 6‐13 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.26, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.33, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mirtazapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.37, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.80, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 TCA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.67, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cornell Scale for Depression in Dementia (CSDD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At week 6‐13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.99, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 6‐9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [‐1.12, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hamilton Depression rating Scale (HDRS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐2.65, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of responders (ITT) at 6‐12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.80, 3.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [0.97, 6.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.17, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of responders (ITT) at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.72, 2.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of patients with remission (ITT) at 6‐12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [1.44, 4.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [1.20, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 TCA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.0 [1.42, 57.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of patients with remission (ITT) at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.80, 3.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Cognitive function endpoint mean scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Mini‐mental state scores at 6‐12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐1.31, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Mini‐mental state scores at 6‐9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐1.14, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in MMSE mean scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 at 6 to13 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.81, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 at 6‐9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐1.90, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Activities of daily living, endpoint values at 6‐13 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.36, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Activities of daily living at 6‐9 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Tolerability: Number of dropouts at 6‐13 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.07, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.88, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.5 [0.68, 17.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 mirtazapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.71, 4.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 older antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.69, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Tolerability: Number of dropouts at 6‐9 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.83, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Safety: number experiencing at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.21, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Older antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.06, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Mirtazapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.93, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [1.08, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Safety: N experiencing at least one event of dry mouth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.23, 2.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Older antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.09, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.01, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Safety: N experiencing at least one event of fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.79, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Older antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.78, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.45, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Safety: N experiencing at least one event of constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.76, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Older antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.68, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.56, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Safety: N experiencing at least one event of dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [1.34, 2.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Older antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.00, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [1.48, 5.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antidepressant versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003944.pub2/references#CD003944-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003944.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003944-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003944-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003944-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD003944-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD003944-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003944-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD003944-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003944-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003944\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003944\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003944\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003944\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003944\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003944.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003944.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003944.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003944.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003944.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728472813"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003944.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728472818"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003944.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec5540afe9367',t:'MTc0MDcyODQ3My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 